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Abstract: 
  
The overall production for the entire process is 22 million doses per year. This production 
capacity is approximately the same as a medium sized facility. Using a baculovirus insect cell 
expression system can reduce the production time of influenza vaccines from 6 months to 4 
months. The other cell line considered, Chinese Hamster Ovaries, was determined to be 
unfavorable due to safety concerns. It was determined that disposable technology would be ideal 
for the process, as it allows production scale up with minimal capital investment. The disposable 
technology employed in the facility was found to be more economically viable than conventional 
multi-use technology. The facility still requires the use of some multi-use components, such as 
chromatography and diafiltration, but single use technology is employed where possible. 
Examining the project, a lifespan of 23 years was determined to be appropriate for demonstrating 
the economic feasibility of the project. It was found that the minimum IRR at current prices was 
33.36%. With a 12% discrete interest rate, the net present value of the facility is $278 million, 
for a total capital investment of $149 million. At this rate, it was also determined that the 
payback period was 2.83 years with a return on investment of 34.42%. From this data, it was 
concluded that the project should proceed as planned. 
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The following report contains information regarding the evaluation of a project for the 
production of trivalent influenza vaccines.  In order to replace the older facility, it was 
determined that a production of 22 million doses per year was needed.  For the facility, two cell 
lines were considered, and it was determined that a baculovirus insect cell expression system 
would best suit the needs for the new plant. 
 
Initially, it was decided that a disposable technology plant design would be utilized.  The 
economic evaluation confirmed this decision.  A time scale evaluation determined that the final 
design could have the entire production line out to market in just short of 4 months, 2 months 
earlier than the older egg-based influenza facility.  A final economic analysis determined that the 
process is economically feasible in the current market, and the project should go through to the 
next design phase. 
 
Assistance was provided by the teams at F.Z. Vaccines, our sister company.  Information 
provided by the teams allowed for the design of the upstream process using the kinetic data from 
the literature they provided on cellular growth and material consumption.  Specific equipment 
costs were provided by suppliers upon request, post design stage.  The team consisted of myself. 
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Abstract 
 
The overall production for the entire process is 22 million doses per year.  This production 
capacity is approximately the same as a medium sized facility.  Using a baculovirus insect cell 
expression system can reduce the production time of influenza vaccines from 6 months to 4 
months.  The other cell line considered, Chinese Hamster Ovaries, was determined to be 
unfavorable due to safety concerns.  It was determined that disposable technology would be ideal 
for the process, as it allows production scale up with minimal capital investment. 
 
The disposable technology employed in the facility was found to be more economically viable 
than conventional multi-use technology.  The facility still requires the use of some multi-use 
components, such as chromatography and diafiltration, but single use technology is employed 
where possible.  Examining the project, a lifespan of 23 years was determined to be appropriate 
for demonstrating the economic feasibility of the project.  It was found that the minimum IRR at 
current prices was 33.36%.  With a 12% discrete interest rate, the net present value of the facility 
is $278 million, for a total capital investment of $149 million.  At this rate, it was also 
determined that the payback period was 2.83 years with a return on investment of 34.42%.  From 
this data, it was concluded that the project should proceed as planned. 
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1.0 Introduction 
 
Influenza is a current world health issue.  Due to the highly infectious nature of the virus, it can 
easily spread from individual to individual.  A global pandemic due to the influenza virus is 
foreseeable in the future.  Thus, it is necessary to develop high yield quick response systems for 
inoculating the public against the spread of the influenza virus. 
 
Vaccination is the current method of preventing infection within in the public.  But in the United 
States, approximately 134.5 million dose were distributed in the 2013/2014 season, which is only 
a fraction of the population [1].  After brief market analysis using these data, and then combing 
them with other market information, an interesting trend was noticed.  It was found that 
influenza consumption increased from the 2000/2001 season, peaked in the 2010/2011 pandemic 
flu season, and then has steadily declined to its current state in the 2013/2014 season [1, 2, 3].  
The data indicate that the demand for influenza vaccines, while large, is not inherently stable, 
and can quickly go up or down from year to year. 
 
1.1 The Two Technologies 
This means that there is a need for a flexible manufacturing process when it comes to influenza 
vaccine production.  Current conventional technology is not inherently capable of performing 
this.  In order to meet fixed production costs related to capital demands, conventional technology 
has to produce a minimum amount to remain economically feasible.  This forces production 
plants to stray from the optimum the production point, leading to higher costs per unit produced 
in the process. 
 
When looking at single use disposable technology, this issue disappears.  While there are some 
capital requirements, the fixed costs due to capital are significantly reduced.  What is more, 
batches are produced in smaller quantities, which allows a more refined approach to production.  
Instead of having to scale a batch to meet the demand, production simply has to scale the number 
of batches to the demand.  The inherent disadvantage to the process is that variable costs go up.  
Each batch requires higher operational costs due to the fact that disposable bags, filters, and 
other items have to be purchased.  This leads to the conclusion that there is a certain point at 
which a disposable technology facility becomes less economically viable than a conventional one 
when it comes to larger scale production. 
 
1.2 Inadequacy of Egg-Based Production 
There is another inherent issue with current influenza vaccine production.  Most vaccines are 
produced using an egg-based production method.  While this method has been shown to be 
effective, there are some issues with this process.  The first is that egg-production methods 
require the preorder and accumulation of millions of chicken eggs.  This requires a lead time of 
up to a year for each batch production year [4].  With a year of lead time, there is little room for 
mistakes during the production process.  If a distinct batch goes bad, the chances are that 
multiple other batches are bad, and that recovery from a mistake is impossible. 
 
The chance of an ineffective batch is, in fact, very high.  Influenza is known for its mutating 
abilities, and could potentially change before the production process is completed.  The result is 
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a vaccine that is ineffective for that year of production, and either cannot be sold, or has to be 
sold at a reduced price due to its reduced effectiveness, if at all possible. 
 
The other inherent issue with egg based vaccines is the potential for contamination during avian 
influenza seasons [5].  This can lead to reduction in influenza vaccine stocks during avian 
influenza pandemics.  The result is an inadequate amount of vaccine due to the feedstock used 
for production. 
 
The last reason for the need to replace egg-based vaccine approaches is individuals with 
allergies.  Egg-based processes can leave residual ovalbumin in the vaccine, which can cause an 
allergic response in individuals who receive the vaccine.  Thus, this drawback reduces the market 
for the vaccine. 
 
These reasons lead to the conclusion that a faster paced, more robust, in terms of feedstock and 
product, process is necessary.  It has been proposed that cells can be grown and used to produce 
vaccines.  The two current cell lines are Chinese Hamster Ovaries (CHO) and baculovirus insect 
cell systems.  Both processes have inherent advantages and disadvantages when it comes to 
processing. 
 
1.3 CHO Cell Lines in Brief 
CHO is a mammalian cell line.  It’s abilities to produce are well established, as over 70% of all 
recombinant proteins are made in CHO cell lines.  They allow for volumetric scalability in bio-
reactors and can grow to titers between 1-5 g/L [6].  The disadvantage of these lines is the need 
for live influenza virus strains in the process [7].  Due to the fact that there are live influenza 
strains used in the process, better security measures are needed to protect employees from 
infection.  In fact, some information indicates the need of a Bio-Safety Level 3 (BSL-3) facility 
for the production of certain avian influenza strains [5].  With CHO cells, there are more issues 
that will be discussed further in section 3.0. 
 
1.4 Baculovirus Insect Cell Systems in Brief 
The other lines considered were the baculovirus insect cell expression systems.  Insect cell lines 
typically used for large scale production are the Sf9 or Sf21 variety from Invitrogen.  These cells 
can be easily grown in serum free media and have been shown to produce product that is highly 
effective in humans [5].  Furthermore, two processes have been developed by both Novavax [7] 
and Protein Sciences [8], with Protein Science’s FDA approved Flublok line being based upon 
this method of production.  This step shows that the ability to produce recombinant influenza 
protein vaccines with insect cell lines is possible. 
 
Also, baculoviruses are only infectious to arthropods [9].  This means that the production 
process, while still BSL-2, is inherently safer for both employees and individuals receiving the 
vaccine.  Novavax [7] and Protein Sciences [8] both state that their processes do not contain 
inactivation steps, due to this fact.  Thus, processes using this technology would have reduced 
materials and capital costs because of the lack of an inactivation step. 
 
Baculovirus insect cell expression systems are temperature and pH sensitive, though [10].  This 
means that carful in process monitoring is required to use these systems.  This also means that 
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the reactors used to produce these lines will be inherently costly, due to the controls needed for 
the process.  The insect cell lines also grow at a pH of 6.2 to 6.4, while the desired product 
protein, hemagglutinin, can be denatured at a pH of 5.5 [11].  While a buffer solution can prevent 
the pH from becoming too low, it is possible that a batch could be ruined due to a low pH, 
leading to higher production costs if too many batches are lost. 
 
1.5 Looking towards the Design 
It is clear that the current methods used for producing influenza vaccines are inadequate.  
Supplies can easily be disrupted by disease, while long lead times can make the process sensitive 
to changes in the virus.  What is more, the market is limited due to allergens present in product.  
The above information shows that there a better possibilities when it comes to the production of 
trivalent influenza vaccines in terms of both technology and media/feedstocks.  This information 
leads to the conclusion that a better design can be developed.  The development of said design is 
the scope of this report, and further explored in the following pages. 
 
2.0 Process Flow Diagrams and Material Balances 
 
For process modelling purposes, a design was run in SuperPro Designer v8.5.  Due to the 
limitations of SuperPro (only allowing 25 units per sheet) and the complexity of the design, the 
upstream and downstream processes were separated into two individual sheets, and their mass 
balances performed separately. 
 
2.1 Upstream Processing 
An overall mass balance of a single batch for the upstream process is provided in Table 1, while 
the process layout is provided in Figure 1.  Individual units were first balanced in order to 
determine if the discrepancies between the inlet and outlet flows were negligible (< 1% error).  
None of the individual units were found to have discrepancies during this portion of the mass 
balance process, though, each reactor did have a small discrepancy. 
 
When performing the calculations for the 
upstream process mass balance, a 
discrepancy was found between the 
amounts of mass flowing in and out of the 
process.  An investigation found that large 
amounts of nitrogen were being consumed 
(according to SuperPro) during the process.  
This discrepancy was rectified by hand in 
an MS Excel mass balance table in the 
overall mass balance section.  It was 
assumed that nitrogen is an inert in the 
process.  By fixing this, the discrepancy was 
reduced from -1200g to -282g, which was 
evaluated to be negligible when looking at 
the total mass flow of the process (< 1% 
error).  Thus, the mass balance was found to 
come to near complete unity. 
Component Input (g/batch) Output (g/batch)
Ammonium 0.00 0.84
Carb. Dioxide 0.00 2.05
Cell Biomass 0.00 554
Glucose 5984 5975
Haemagglutinin 0.00 25.17
L-Glutamine 997 990
Lactate 0.00 4.30
Media 23736 23166
NaHCO3 349.06 349.06
Nitrogen 293780 293780
Oxygen 89186 89467
WFI 966245 966245
Total 1380277 1380559
-282.49
Overall Mass Balance Upstream
Discrepancy (g/batch)
Table 1: Upstream Mass Balance 
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Coloring is provided in order to aid the reader in following the process.  When looking at Figure 
1, it should be noted that the infection bioreactor is sized as a 200L bioreactor.  This is a 
potential design area of improvement, as a using a 100L working volume bioreactor as a 
substitute for a 50L working volume wave bioreactor can make the process somewhat less 
efficient when it comes to storage.  Modifying a wave bioreactor for a smaller volume should be 
considered for the future. 
 
2.2 Downstream Processing 
The mass balance for the downstream process came to unity without any issues during the 
evaluation.  Individual mass balances were performed over each unit, and each unit was found to 
have negligible errors.  When the total mass balance was performed, again, negligible 
discrepancies were found in the process.  The total mass balance is summarized in Table 2. 
 
It should be noted that there are some components of the mass balance table that are zero in and 
out.  These components were originally part of the design, but later eliminated when deemed 
unnecessary.  It was also assumed that the process was air tight for simplification of the 
calculations.  This assumption is not 100% accurate, as parts of the process can come into 
contact with air.  It was assumed that Good Manufacturing Practices would be performed and 
contact with potential 
contaminants, such as air, 
would be eliminated. 
 
Figure 2 shows a general 
process overview of the 
downstream process.  
Multiple upstream processes 
can utilize a single 
downstream process, which 
is why there is a separation 
between the process flow 
diagrams. 
 
It should be noted that some 
streams do not contain mass 
flow rates, as they are simple 
cleaning steps.  Other 
streams are not included due 
to the potential amount of 
clutter that adding a label to 
these streams would create.  
Lastly, some streams are 
presented in kilograms, while 
others are in grams, which 
could potentially confuse the 
reader if unnoticed. 
Component Input (g/batch) Output (g/batch)
Ammonium 0 0
Carb. Dioxide 0 0
Cell Biomass 554 554
Glucose 5958 5958
Haemagglutinin 25.2 25.2
HCl 2.84 2.84
Inulin 8500 8500
Isopropanol 2637 2637
KCl 0 0
KH2PO4 0 0
L-Glutamine 987 987
Lactate 4.30 4.30
Media 23096 23096
Na2HPO4 737 737
NaH2PO4 182 182
NaHCO3 348 348
Nitrogen 0 0
Oxygen 0 0
Sodium Chloride 9707 9707
Sodium Hydroxid 435 435
Water 0 0
WFI 1670098 1670098
Total 1723272 1723272
-0.027
Overall Mass Balance Downstream
Discrepancy (g/batch)
Table 2: Downstream Mass Balance 
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3.0 Process Description 
 
Both the upstream and downstream processes had multiple considerations and evaluations that 
had to be performed.  This description follows the process in the order of the stream flows. 
 
3.1 Upstream Processing 
For the upstream processing side, there were three primary considerations that had to be 
examined.  The first consideration was the cell line that was going to be used.  As stated in the 
introduction, there were a number of issues regarding both cell lines, but ultimately insect cells 
were chosen for use.  The second consideration was to use disposable or conventional 
technology for the bioreactor processes.  Initial research indicated that disposable technology 
was more favorable than conventional technology.  After designing the process, detailed 
economic evaluations were performed in order to compare both technologies, and it was found 
that this decision was justified.  The final consideration was whether to manufacture or purchase 
the media for cellular production.  Manufacturing media proved to be more difficult, as most 
formulations are confidential, and cell lines show preferences when it comes to processing. 
 
3.1.1 Cell Line Decisions 
The two cell lines considered were CHO and insect cell systems.  The first cell line considered 
was CHO.  CHO presented a viable solution, as over 70% of recombinant proteins are produced 
using CHO cellular expression systems.  They can be grown in high concentrations and provide 
easier volumetric scalability when it comes to batch modelling [6].  There are a number of 
inherent disadvantages, though, when it comes to processing with these types of cells. 
 
Due to the fact that CHO are mammalian cells, they require live influenza virus in order to infect 
[7].  While this makes relating the vaccine to humans easier, it means that more stringent safety 
measures are required when it comes to processing these types of cell lines.  In fact, some 
evaluations recommend using BSL-3 facilities when it comes to using these cell lines and avian 
influenza viruses, due to the danger presented to employees while processing [5].  Higher level 
facilities require more stringent regulations and methods of control when it comes to processing, 
increasing costs along with inherent danger. 
 
A second similar issue arises in CHO cells as well.  Due to their relatability to humans, other 
human viruses can more easily contaminate the cellular stock [12].  Add in the fact that CHO 
cells are highly susceptible to lysing when subjected to shear forces (such as mixing) [13], and 
the overall process using this cell line becomes more costly due to more evaluations and testing, 
and less robust when it comes to process designs. 
 
Insect cell lines showed immediate promise.  Experimental evaluations showed that vaccines 
produced from insect cells were effective in humans.  The added fact that insect cells could 
easily be put into chemically defined serum free media without adaptation made them favorable 
for the process [5].  Further examination found that both Novavax [7] and Protein Sciences [8] 
had developed processes for influenza vaccine production using insect cell lines.  Insect cell 
lines, such as Invitrogen’s Sf9, which can be used in large scale processing, could also be grown 
in suspension at 27°C [10].  This meant that energy inputs for heating the cells would be 
minimal, as this temperature is barely above room temperature. 
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Another advantage to insect cell lines is the fact that baculoviruses, the viruses used to infect 
insect cell lines, are only infectious to arthropods [9].  Two sources, Novavax [7] and Protein 
Sciences [8], confirm this.  Both companies stated that a downstream inactivation step was 
unnecessary when it came to processing.  In many cases, hazardous chemicals such as formalin, 
are used for the inactivation step downstream.  Eliminating this hazardous step completely not 
only reduces costs, but also follows some of the guidelines set by the 12 Principles of Green 
Engineering [14].  Thus, a better process could be designed using insect cell lines. 
 
Some disadvantages for insect cell lines became clear, though.  While lines, such as Sf9, are 
robust when it comes to shear forces, factors such as pH and temperature can greatly inhibit 
growth [10].  What is more, insect cells grow at a pH around 6.2 to 6.4, while hemagglutinin, the 
target product, can be denatured at a pH of 5.5 [11].  This could potentially lead to a higher 
amount of batches lost during processing, due to denaturing of the product. 
 
Based on the information stated above, it was decided to use insect cell lines, and more 
specifically, Sf9 insect cell lines.  Sf9 insect cells show robust behavior during processing [10], 
produce minimal waste products that inferred with growth [15], and have ample research on 
kinetics data and behavior in process type environments [10, 15, 16, 17].  Some sources had 
quantified production quantities of hemagglutinin produced based on total amount of cells [17], 
which reduced the difficulty of designing the process.  Lastly, there is already an insect cell line 
based influenza vaccine entering the market (Flublok), showing that the process can be 
developed successfully [18]. 
 
3.1.2 Technological Decisions: Disposable or Conventional 
There were two technologies considered: Disposable and conventional.  It was determined early 
on in the process that disposable technology would be the best possible method when it came to 
the bioreactor process train. 
 
Current conventional technology uses Steam-in-Place (SIP) and Clean-in-Place (CIP) processes 
after each run.  This requires large amounts of capital investments to be made in the process.  It 
was estimated that the cost of a conventional style facility would be around $600 million.  A 
similar sized disposable facility was found to have a capital investment of only $40 million, 12x 
less than the conventional design [19].  Other economic comparisons based on conventional 
technology found the net present value (NPV) of a conventional facility was higher, but factoring 
in time till production increased the NPV of disposable technology [20]. 
 
Looking further into the technology, it was found that every upstream process had a disposable 
version.  While this increased operational costs of the facilities, this trade off was deemed 
effective in terms of long run economics.  In the long run, initial investments have high values 
while revenue returns diminish over time due to inflation, interest, and other external factors.  
Thus, a smaller initial investment with slightly larger operational costs in the future was deemed 
more economically viable.  Both processes, though, were evaluated in order to ensure this 
assumption was correct and is discussed further in section 12.0 of this report. 
 
Another factor that was considered was sterility of the process.  As stated earlier, conventional 
technologies use SIP and CIP methods, while disposable technology is simply one use and done.  
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The bags used in disposable processing are certified as sterile when delivered, thus reducing the 
need for validation.  On the other hand, conventional technology requires extensive validation, 
while still having an inherent risk of cross contamination and carryover between batches [21].  
This could potentially lead to more batches lost during production, due to contamination, and 
thus, increasing the costs of the process or potentially limiting the process production altogether. 
 
There was one final consideration which was a Contract Manufacturer (CMO).  This option was 
considered before conventional technology was eliminated.  According to literature about 
CMOs, a large $400 million conventional facility would need to produce at least 4 products to be 
more economically viable than outsourcing to a CMO [22].  However, when it was determined 
that the disposable technology method was more economical than a conventional method with an 
estimated investment of $40 million, the CMO became significantly less advantageous.  Thus, 
the CMO option was also eliminated. 
 
The final design was determined to be a disposable technology based fed-batch train.  Fed batch 
trains followed a batch style processing, as was specified by the company, but simply added 
additional nutrients during processing.  This improved yields in both hemagglutinin and cellular 
production rates [17], thus reducing the materials costs, batches, and time to produce.  In the 
initial problem statement, it was also recommended that production scales of GlaxoSmithKline 
(GSK) be looked into.  In the 2012/2013 season, GSK produced 21 million doses and was sold 
out by early January.  GSK predicted it would produce 22 to 24 million doses in 2013/2014 [23].  
Thus, it was assumed that 22 million doses is a reasonable production scale. 
 
3.1.3 Media Decision 
The requirements for media preparation were that the media had to be prepared from a dry 
powder format, was chemically defined, and serum free (animal free facility).  Literature 
regarding the actual content of the media was limited, though present [17].  This referenced 
literature example, though, lacked concentration data for the formulation of a media blend that 
could grow cell cultures. 
 
Most kinetic data for the growth of cellular cultures utilized commercial media, such as Sf-900 
II, ExCell-405, and ExCell-420.  Thus, in order to utilize this kinetic data accurately, one of the 
commercial media had to be used.  General growth information presented in some sources, such 
as Baculovirus and Insect Cell Expression [9] had kinetic data that was initially utilized for 
modelling.  Certain media, such as Sf-900, were only shipped in liquid form.  Thus, they were 
immediately eliminated.  The final decision fell on ExCell-420, produced by Sigma Aldrich.  
This line had a powder component and literature could be found regarding its growth rate [16], 
which was determined to be similar to the kinetic data presented in Baculovirus and Insect Cell 
Expression.  Using a Multiplicity of Infection of 1.0, ample amounts of hemagglutinin could be 
produced, as indicated by the literature [17].  Lastly, 5 upstream sections will be utilized in order 
to ensure that the entire product is produced in 85 days.  Approximately 48 batches were needed 
to produce 22 million doses, with 2 batches factored in for mistakes in the process. 
 
3.2 Downstream Processing 
There were five primary processes when it came to downstream processing: Harvest, 
inactivation, capture, purification, and concentration/stabilization for shipment.  Each one is 
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discussed in its own individual section.  The primary purpose of the downstream process is to 
recover hemagglutinin, the external viral antigen.  Instead of harvesting the virus, it was 
determined that it would be more effective to harvest the antigen, which is the chemical the body 
targets during an infection. 
 
3.2.1 Harvesting the Hemagglutinin 
The first part of the process is removing the solid biomass from the stream leaving the upstream 
process.  Based on other producers, centrifugation using a disk stack centrifuge followed by 
depth filtration was the most ideal process [8].  The disk stack centrifuge requires large quantities 
of water to run, according to SuperPro Designer v8.5, but concentrates most of the 
hemagglutinin in a pellet formed during the process.  This step is especially helpful, as modeling 
data in SuperPro Designer indicated that glucose, the media, and L-glutamine were largely 
removed during this process.  The disadvantage is that cellular biomass, host cell DNA 
(hcDNA), and other proteins still remained in the pellet. 
 
The pellet was re-suspended in a buffering solution that would be utilized in the capturing 
process.  The ratio of solution to pellet was given as 6.4g/225mL of solution [24].  The 
solubilized pellet was sent through a depth filtration cartridge.  This step was used in order to 
remove the majority of the cellular biomass in the process stream.  After each run, the cartridge 
was changed, being one of the disposable technologies employed in the downstream process. 
 
After depth filtration, the process was then sent through a diafiltration step.  The purpose of the 
diafiltration step is to remove excess impurities, such as glucose, L-glutamine, and media that 
might still be remaining in the process.  From here, the process is sent to a storage tank for 
capturing.  Diafiltration, though, does not remove hcDNA or other proteins in the process, 
meaning that other methods of purification are necessary. 
 
It should be noted that in these processes, there are 3 tanks used to hold product.  The tank that 
occurs before the centrifugation step, holds the product coming in from the upstream design.  In 
order to keep the process on schedule, the centrifuge must run as this tank is filling.  The 
centrifuge, though, has a lower flow rate than the rest of the processes, and thus, cannot catch up 
to the filling of the tank.  The other two tanks are intermediate storage tanks that utilize 
disposable technology for their processes.  This was done in order to minimize SIP and CIP 
procedures needed in the downstream process. 
 
3.2.2 Inactivation of the Hemagglutinin 
Because of the expression system that was selected for this process, an inactivation step was 
unnecessary for this process.  Theoretically, “inactivation” comes from the physical removal of 
the hcDNA and other proteins, but this is not traditional inactivation.  Two producers, Novavax 
[7] and Protein Sciences [8] confirm that this step is unnecessary for baculovirus insect cell 
expression systems.  Further investigation found that this is due to the fact that baculoviruses are 
only infectious to arthropods [9].  Protein Sciences has also validated the product that it produces 
with the FDA and has proven that it is effective in humans [18].  Standard inactivation requires 
chemicals that are potentially harmful if left in the process, or improperly removed.  Thus, 
eliminating this step completely from the process is highly desirable and follows the Principles 
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of Green Engineering [14].  Based on this overwhelming amount of information, the inactivation 
step can be removed from the downstream process safely. 
 
3.2.3 Capturing the Hemagglutinin 
The next step in the process is the use of an anionic exchange membrane (AEX).  Other 
processes use an anionic exchange chromatography (AEC) or size exclusion chromatography 
(SEC), followed by membrane filtration for this step.  It was determined that using an AEX 
process would be more efficient.  The reason is that AEC had lower yields of hemagglutinin, 
according to the literature.  SEC has high yields, and is effective at removing other impurities in 
the system.  However, SEC was deemed expensive for large scale processing.  Relevant 
information indicated that AEC had an overall yield of 80% of hemagglutinin [25], while AEX 
had yields of up to 86% [26].  This minor difference resulted in the need for more production 
runs, thus, AEX was favored. 
 
The particular membrane used in this process is Sartobind Q.  It has the capability to process 67 
L/m2/hr.  Further investigation found that AEX removed 77% of residual protein in the process, 
though, no hcDNA was removed, meaning that some further purification was necessary further 
downstream of the process [26].  What makes AEX ideal is that AEX uses a salt based bind and 
elute method, similar to AEC.  AEX binds proteins that flow through the membrane, while 
hemagglutinin and residual hcDNA pass through during the loading phase.  Using a salt gradient, 
everything captured is eluted from the membrane.  This process only requires a salt and buffer 
solution, which was already utilized in the process.  Thus, it was again determined to be 
favorable as no extra chemicals are added during processing. 
 
Pre and post storage tanks utilized in this step are disposable.  This reduces the time needed to 
SIP and CIP for the process.  It also reduces the risk of cross contamination or contamination 
getting into the tanks during the process. 
 
3.2.4 Purification of the Hemagglutinin 
Following the AEX process is another diafiltration step.  This step removed residual salt in the 
process for the next chromatographic exchange process, hydrophobic interaction 
chromatography (HIC).  HIC behaves similarly to SEC and affinity chromatography (AC).  AC 
uses a ligand to bind the hemagglutinin until it is forced to elute the protein, making AC highly 
selective when it comes to binding.  SEC uses the various sizes of molecules to exclude larger 
molecules while processing.  The HIC resin chosen for this process was GE’s CaptoCore 700, 
which exhibited these exact properties, and has been tested for hemagglutinin processing [27]. 
 
The internal ligand in the chromatography beads binds to hemagglutinin, similar to AC.  At the 
same time, a coating around the bead has pores that exclude molecules of larger sizes, similar to 
SEC.  Once other materials have passed through, using a higher salt concentration, the 
hemagglutinin is eluted from the chromatography resin.  CaptoCore 700 allowed for the recovery 
of 94% of the hemagglutinin that was loaded onto the column.  According to GE, nearly all of 
the residual protein was removed during this process, and ~50% of hcDNA was removed in this 
step.  An investigation by GE found that HIC using their processing techniques and two 
chromatography type processes removed the majority of the hcDNA and residual proteins in the 
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process stream.  Using an added filtration step, it was determined that hcDNA and residual 
proteins can be removed down to an approved level [27]. 
 
Two more holding tanks are utilized in this step.  Again, these tanks are disposable for the 
reasons stated above.  However, these holding tanks are smaller than ones utilized earlier in the 
process.  Also, the HIC process does not use additional components, other than phosphate 
buffered saline, as a carrier for the hemagglutinin.  Thus, the need for other chemicals in the 
process is eliminated, again. 
 
3.2.5 Concentration/Stabilization Steps for Production Hemagglutinin 
The final steps involve a diafiltration step that concentrates the solution.  This is done in order to 
reduce the needed steam to freeze dry the hemagglutinin in the final step.  After filtration, the 
system passes through an ultrafiltration and a sterile filtration step, before being freeze dried.  
The ultrafiltration and the sterile filtration remove nearly all of the remaining hcDNA and protein 
in the process that were not removed by the chromatography and other filtration steps.  The 
literature indicates that each step yields of 97% of hemagglutinin, while removing 84% of any 
residual protein and 67% of the hcDNA sent through the filter in each step [28]. 
 
Before freeze drying, the final product is stored in a disposable container.  At this point, more 
salt, phosphate buffer, and inulin sugar are added.  Research indicates that the inulin acts as a 
stabilizing agent for storage before transportation.  The recommended hemagglutinin to inulin 
ratio was 1:500.  Stabilization of hemagglutinin lasts between 3 months to a year after freeze 
drying, and the potency of the virus was still viable, even when stored at 20°C.  It was 
recommended, though, that the vaccine after preparation be stored at 4°C [29, 30]. 
 
3.2.6 Final Onsite Storage 
Upon freeze drying, the entirety of the batch is stored in a single 10L bag.  This unit is a dry 
powder that can be hydrated as needed with the other 3 parts of the vaccine in order to form the 
entire vaccine dose.  The needed amount can be weighed out, based on the concentration of the 
dry power, and mixed with the other dry powder vaccine units at the formulation and filling 
processes so that the vaccine contains 15µg/strain/dose.  The area for storage is held at a 
temperature of 4°C, due to the fact that this is the temperature that the vaccine unit is the most 
stable at [30].  By holding it at this temperature, minimal amounts of the hemagglutinin will 
degrade while waiting for shipment from the production facility. 
 
4.0 Energy Balance and Utilities Requirements 
 
The following is a summary of the utilities and energy balances for the entire process.  The total 
of the utilities was estimated using calculation factors provided by Novais et al [20] along with 
other cost estimation factors in Biochemical Engineering [31]. 
 
4.1 Energy Balances 
The energy flowing in and out with the streams were calculated using SuperPro.  Not all mass 
left the system in the upstream process, which meant that the mass which remained in storage 
containers was considered to be lost during disposal.  Once the streams were summed, pumping 
energy and steam energy (freeze drying) were factored in.  In both cases, a positive amount of 
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energy resulted, which was accounted for as energy that left the processes and was not utilized 
during production. 
 
 
 
 
 
It is clear from the balances that a lot of energy is lost during the freeze drying process.  Further 
investigation should be done in order to determine if there is a way to optimize the process, or 
reduce the energy losses of the freeze drying unit. 
 
4.2 Utilities 
The overall utilities are summarized in the table below.  As stated above, estimation was used for 
the energy consumption of the HVAC system, building, materials landfilled (bags, filters, etc.), 
and then a general contingency factor, provided by the materials referenced above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Input on Streams (kJ/batch) 110877
Output on Sreams (kJ/batch) -119460
Residual in Tanks (kJ/batch) -298
Pumping Input (kJ/batch) 91800
Lost to Surroundings(kJ/batch) -82919
Balance 0
Overall Energy Balance Upstream
Input on Streams (kJ/batch) 186591
Output on Streams (kJ/batch) -248560
Input from Pumps (kJ/batch) 33210
Input from Steam (kJ/batch) 6416758
Loss to Surroundings (kJ/batch) -6387998
Balance 0
Overall Energy Balance Downstream
Table 3: Overall Energy Balance 
Upstream 
Table 4: Overall Energy Balance 
Downstream 
Table 5: Upstream Utilities and Costs 
Sections 5 Batches/Section 10
Process Electricity 2321.85 kW-hr/batch
Electricity to Chill Water 2945.11 kW-hr/batch
Water Utility for Cooling 126500 L/batch
Includes heating, agitation, and sparging
Chilled Water (5 Deg C and 0.5Mpa) 126500 kg/batch
Tap Water (20C, 0.5Mpa) 84.38 kJ/kg
Chilled Water (5 Deg C) 21.52 kJ/kg
Pumping Usage 339.53 hr/Batch
Pumping Power (75W, 75% Eff) 34.0 kW-hr/Batch
Water Utility Cost 3,434.48$          
Electricity for Cooling 7,362.77$          
Electricity for Processing 5,804.63$          
Electricity for Pumping 84.88$                
Sewage 31,625.00$        
Upstream
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Table 6: Downstream Utilities and Costs 
Sections 1 Batches/Section 50
Process Electricity 102.17 kW-hr/batch
Heating Electricity 1782 kW-hr/batch
Water Utility for Steam 2417 L/batch
Water Utility for Else (CIP, etc) 22596.7 L/batch
Conversion of Water to Steam at 152 Deg. C
Steam Heating 2417 kg/batch
Tap Water (Deg. 20C, 0.5Mpa) 84 kJ/kg
Sat. Water (Deg. 151.831 C) 632 kJ/kg
Energy of Evaporation 2107 kJ/kg
Energy Per Batch 6417 MJ/batch
Pumping Usage 123 hr/Batch
Pumping Power (75W, 75% Eff) 12.3 kW-hr/Batch
Electricity for Processing 255.42$           
Electricity for Heating 4,456.08$        
Electricity for Pumping 30.77$              
Water Utility for Steam 65.61$              
Water Utility for Else 613.50$           
Sewage 6,253.35$        
Downstream
Liquid Upstream 6,325,000        L/yr
Liquid Downstream 1,250,669        L/yr
Liquid Process 79,553              L/yr
Total Liquid to Process 7,655,222        L/yr
UV Power to Process 7,655.22          kW-hr/yr
Electricity to Process 30,620.89        kW-hr/yr
Electricity for Processing 1,531.04$        
HEPA Vac. Air Processing 30,000.00$           
General Electricity 10,000.00$           
Landfill for Disposables 124,000.00$         
Contingency (20%) 51,813.93$           
Total Utilities 277,331.45$         
Extra Utilities to be Considered
Total Utilities
UV Treatment
Table 7: Other Utilities and Total Utilities 
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5.0 Equipment List and Unit Descriptions 
 
The following is a summary of process equipment that is needed for the production in each 
section.  This includes both equipment and disposables.  A brief explanation of each piece of 
equipment follows the tables.  Some equipment, such as the UV pre-sewage kill unit and pumps 
are not included in the PFD, but are included in the equipment analysis. 
 
5.1 Equipment Lists 
The following is a list of utilized equipment for processing.  Note that each table includes 
equipment for a single section in the process for the sake of simplicity: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Operational Sections 1
Freeze Dryer - 39.15kg Sub. Capacity 1
Disk Stack Centrifuge - 71.36L/hr 1
Anionic Exchange Membrane 1
CC700 Chromatography Column - 12.59L 1
Diafilter - Area 1.85m2 1
Diafilter - Area 0.09m2 1
Diafilter - Area 1.22m2 1
Ultra Filter - Area 0.34m2 1
Sterile Filter - Industrial 1
Depth Filter - Industrial 1
Blending Tank - 1110L 1
Skid for Disposable Bag - 50L 2
Skid for Disposable Bag - 200L 5
UV Cleaning System 1
Variable Peristaltic Pumps - 3.4LPM (10% Backup) 15
Downstream Equipment per Section
Table 8: Upstream Equipment Cost Summary 
Table 9: Downstream Equipment Cost Summary 
Operational Sections 5
Wave Bioreactor 20/50 1
Wave Bioreactor 100/200 1
XDR Disposable Reactor - 200L 1
XDR Disposable Reactor - 1000L 1
Skid for Disposable Bag - 50L 3
Skid for Disposable Bag - 1000L 1
Variable Peristaltic Pump - 3.4LPM (10% Backup) 14
Sterile Tube Fuser-Dry 1
Upstream Equipment per Section
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5.2 Unit Descriptions 
The following is a description of each unit in the process.  It has been divided into two sections: 
Upstream and downstream.  It should be noted that where pumping is mentioned, a peristaltic 
pump is used for the transfer.  Generally, pumps are used where sterile filters occur (such as 
tanks/storage bags), other types of filters, chromatography columns, and reactors.  All bags 
contain 0.22µm sterile filters on them to prevent contamination during processing.  Transfer 
pumps have a 180L/hr flow rate, based on the peristaltic pumps that were selected. 
 
5.2.1 Upstream Units 
The upstream portion of the process is used to grow and infect the feedstock cells.  Insect cell 
lines are kept at a temperature of 27°C for optimal growth [10].  The cells are diluted to 
concentrations of 5.00x105 cells/mL and grown till they are in the upper log phase of growth at 
2.77x106 cells/mL, where they are then diluted back down to 5.00x105 cells/mL and grown again 
[9]. 
 
In the upstream portion of the section, the first unit is the T-flask.  This is where the 1mL cell 
culture is first introduced to the process using injection techniques.  19mL of media and air are 
added in this unit, and the reaction takes place in a shaken T-flask for 52 hours. 
 
The process is then moved to a larger 2.2L roller bottle.  This is the first process that uses a fed-
batch design.  In the first stage, around 90mL of media is pumped into the unit as the insect cells 
grow for 52 hours.  Then, the media transfer rate is increased to 600mL over 52 hours as cellular 
growth continues for the process.  Once completed, the process is pumped out of the reaction 
vessel and into the 20/50 wave bioreactor. 
 
Using the fed batch design again, the process volume is increased from 610mL to 3.4L over 52 
hours, followed by another fed batch reaction increasing the working volume to 18.23L over 52 
hours.  This is the last stage of the process before the process is split: half of the volume of the 
tank is sent to the infection reaction wave bioreactor for seeding, and the other half is sent to be 
increased in volume to the full batch size cellular volume.  Before splitting, approximately 
100mL of cellular solution is removed.  These components concentrated to 1x107 cells/mL and 
then split into 1mL phials and stored in the vapor head space of a liquid nitrogen freezer.  These 
phials are used in all the other batches for the year starting in the T-Flask unit mentioned above. 
 
The infection reaction uses a 100/200L wave bioreactor.  This is the part of the process where the 
cells are infected with the baculovirus.  Pumping the media for inoculation into the system, the 
working volume is increased to 50L.  From there, air is added along with a phial of the 
baculovirus for the purpose of infecting the cells at a multiplicity of infection (MOI) of 1.0 [17].  
The reaction is allowed to proceed for 120 hours, while the process is held at constant 
temperature, and is then cooled to 4°C for storage [32].  This process waits while the main 
process produces the cellular batch that is going to be infected. 
 
From the 20/50 wave bioreactor, the other half of the process enters a small XDR 200L stirred 
tank bioreactor.  The cellular batch is again fed over 52 hours to a volume of 50.5L.  This step is 
important as it is the last step before the cells are passaged to the main production bioreactor.  It 
was considered performing two growth steps in this reactor using a 500L bioreactor, but 50L is 
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barely 10% of the total volume, making it an inefficient use of the reactor’s size.  Thus, it was 
decided that the batch would be grown to 50L, and passaged on to the main production reactor. 
 
The main production reactor has a total volume of 2000L and a working volume of 1000L.  
Normally, one does not process at less than 10% of the total volume and 5% is considered to be 
the absolute minimum limit.  However, the fed batch process quickly adds volume to the 
reaction, increasing the working volume to 100L within a few hours.  Thus, this is considered to 
be acceptable for this process.  The 50L batch is grown in a fed batch style to 280L over 52 
hours, and then to 950L over 21 hours.  At this point, the cells are ready to have the virus 
introduced at an MOI of 1.0 from the infection wave bioreactor.  The total working volume 
becomes 1000L and the infection is allowed to proceed for 72 hours, which is confirmed as the 
most ideal time by multiple sources [9, 17].  After this, the process is then removed from the 
main bioreactor and sent to the downstream process. 
 
5.2.2 Downstream Units 
The main bioreactor pumps into a large downstream tank.  As the main process feeds into the 
tank, a pump moves fluid through a disk stack centrifuge that begins to concentrate the fluid 
leaving the tank.  The centrifuge concentrates the cellular mass and hemagglutinin in the pellet, 
while the supernatant is discarded from the process [13].  The pellet is then re-suspended in the 
phosphate buffer saline solution (134L) that will be used in the AEX process further downstream 
in the storage tank following the centrifugation step. Disk stack centrifugation is the most 
common method for this process, which is why it is used. 
 
It should be noted that disk stack centrifugation removes a large amount of waste in the stream 
that might clog downstream filters, but it is recommended that the fluid be pumped through a 
0.22µm depth filter immediately afterwards to ensure that no other particulates (especially 
biomass) proceed further downstream [9].  It is also recommended that after these steps, a 
diafiltration step be used.  This further removes impurities from the process, allowing for easier 
processing downstream [9]. 
 
From here, the extra salt and buffer solution is added to ensure that the process is at around 0.7M 
NaCl and 20mM phosphate buffer.  Then, the solution is pumped onto the AEX membrane.  
Hemagglutinin passes through, while excess proteins are captured by the membrane.  Then, a 
1.5M NaCl and 20mM phosphate buffer solution is used to elute the components trapped on the 
membrane.  The membrane is then cleaned with a 0.1M HCl and 2M NaCl solution followed by 
a 1M NaOH and 1M NaCl solution.  The membrane is then sanitized/equilibriated for 1 hour 
using 0.5M NaOH, after which point ready to be used again [25]. 
 
Nothing is added in the AEX storage tank because for the HIC column, there is too much salt in 
the solution.  Thus, the system is pumped through a diafiltration process and into another storage 
tank where phosphate buffer is added.  The diafiltration in this step actually halves the total 
volume of the solution (134L to 67L) in order to concentrate the process, thus, reducing the 
volumes being processed.  At this point, the salt concentration is 0.15M NaCl and more 
phosphate buffer is added to bring it to 20mM phosphate buffer [27, 33]. 
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From here, the process is sent onto a CaptoCore 700 HIC column.  1.89L of CaptoCore 700 is 
needed to remove hcDNA and other proteins in the process on the 12.6L column.  The beads are 
equilibriated with 0.15M NaCl and 20mM phosphate buffer solution, and then the fluid in the 
CC700 S&P tank are sent through the column.  Other proteins and hcDNA continue through the 
column, while hemagglutinin is captured by the beads.  Then, using a high salt concentration of 
0.75M NaCl in 20mM phosphate buffer, the hemagglutinin is eluted from the beads in the 
column.  It is then washed with 1M NaOH in 30% isopropanol solution.  Afterwards, it is 
sanitized with 1M NaOH.  Lastly, the column is equilibriated with 0.15M NaCl and 20mM 
phosphate buffer to prepare it for the next batch [27, 33]. 
 
The purified process is then pumped through another diafiltration device.  The column reduces 
the total volume to 9.4L, and the diafilter removes excess salt and buffer in the solution.  From 
there, the process passes through a 1 micron 750kDa ultrafilter that removes more hcDNA and 
proteins, and is then followed by another sterile filter of 0.22µm in size to remove other excess 
proteins, hcDNA, and any possible contaminants in the process [26]. 
 
Before freeze drying, the final buffer solution is added, and the process is diluted with roughly 
30L of injection water.  Adding 8.5kg of inulin sugar gives a stabilizing matrix for the 
hemagglutinin during the freeze drying process [29, 30].  This gives a 5mM Phosphate buffering 
solution with 0.7M NaCl solution.  The full 46.7L (somewhat increased due to all the mass that 
is added) is then passed into the freeze dryer where 39.15kg of water is removed, and the final 
product containing hemagglutinin, NaCl, phosphate buffer, and inulin is left (~8.7kg). 
 
The final product is then stored the shipping area in a 10L bag that is vacuum sealed.  The 
approximate temperature is approximately 4°C for maximum stability.  This is also a safety 
assurance, considering stability has been shown for the powdered matrix in temperatures as a 
high as 20°C [30].  The bulk storage has a consistent concentration which allows for easier 
processing in the final fill and finish part of the vaccine process.  The powder of the other 
vaccine units can be combined with each other in proper ratios with added phosphate buffer to 
form a vaccine solution containing phosphate buffered saline and 15µg of each strain per dose, 
as described by the World Health Organization [12]. 
 
6.0 Equipment Specification Sheet 
 
The following is a list of equipment and their approximate specifications based on SuperPro 
Designer v8.5.  Notation is based on process flow sheet above. 
 
6.1 Upstream Process Equipment 
The following list contains upstream process equipment (excluding pumps and other external 
components). 
 
Lab Flask 
 -100mL volume 
 -Working volume 50% of max volume 
 -1 unit per skid rack 
 
20 
 
Roller Bottle 
 -2.2L volume 
 -Working volume 50% of max volume 
 -1 unit per skid per rack 
 
RBR Storage (Roller Bottle Storage) 
 -1.00L volume 
 -Working volume 100% of max volume 
 -1 unit per skid per rack 
 
Small WaveRctr (20/50 GE Wave Bioreactor) 
 -50L volume 
 -Working volume 50% of max volume 
 -1 skid per container 
 
50L Store, Infection Media, and STR Store (3x 50L Skids and Disposable Bags) 
 -50L volume 
 -0.22µm sterile filter 
 -Working volume 50% of max volume 
 -Needs to be mixing approved 
 -1 skid per container 
 
Infection Rxn (100/200 GE Wave Bioreactor) 
 -200L volume 
 -Working volume 50% of max volume 
 -1 skid per container 
 
Small STR (GE XDR 200L Disposable Reactor) 
 -200L volume 
 -Working volume 50% of max volume 
 -1 skid per container 
 
Production STR (GE XDR 1000L Disposable Reactor) 
 -2000L volume 
 -Working volume 50% of max volume 
 -1 skid per container 
 
1000L Store (1000L Skid and Disposable Bag) 
 -1000L volume 
 -0.22µm sterile filter 
 -Working volume 100% of max volume 
 -Needs to be mixing approved 
 -1 skid per container 
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6.2 Downstream Process Equipment 
The following list contains downstream equipment and their unit descriptions (excluding pumps 
and excess process units). 
 
Upstream Store (Blending Tank) 
 -1110L volume 
 -Working volume 90% of max volume 
 -2.334m Height 
 -0.778m Diameter 
 
UltraCent (Disk Stack Centrifuge) 
 -Sigma Factor 3030.97m2 
 -Throughput 71.36L/hr 
 
DF Storage, AEX Hold, and CC700 S&P (3x 200L Skid and Disposable Bag) 
 -200L volume 
 -Working volume 100% of max volume 
 -Needs to be mixing approved 
 -1 skid per container 
 
Depth Filter 
 -0.22micron Depth Filter Cartridge 
 -10.00m2 Area 
 -5 cartridge slots/unit 
 -1 working cartridge/unit 
 
DiaFilt Storage and AEX Store (2x 200L Skid and Disposable Bag 
 -200L Volume 
 -Working Volume 100% of max volume 
 -1 skid per container 
 
Impurity Remove (Diafiltration) 
 -1.218m2 membrane area 
 
AEX Process (AEX Membrane) 
 -Sartobind Q 30” 
 -1.964m2 membrane area/total membrane area 
 -275.000 micron membrane thickness 
 -14.545 layers 
 -0.540 L membrane volume/total membrane volume 
 -1350.00cm2 bed frontal area/total bed frontal area 
 -4.000mm bed height 
 -1.000 over design factor 
 
De-Salting (Diafiltration) 
 -1.853m2 membrane area 
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CC700 Column (HIC Chromatography Column) 
 *Column Shape and Dimensions 
-Circular Design 
 -1.000m height 
 -0.127m diameter 
 -1.200m max diameter 
 -12.59 volume 
 
 *Column Sediment Bed Dimensions 
 -0.150m height 
 -0.100m min height 
 -Volume 1.89L 
 -1.00 overdesign factor 
 
DiaF Store (50L Skid and Disposable Bag) 
 -50L volume 
 -Working volume 100% of max volume 
 -1 skid per container 
 
Concentration (Diafiltration) 
 -0.088m2 membrane area 
 
UF Final (Ultrafiltration) 
 -0.3380m2 filter area 
 -750 kDa and 1 micron filter 
 
Sterile Filt (Sterile Filtration) 
 -0.22µm filter 
 -10.00m2 filter area 
 -5 max cartridge slots 
 -1 cartridge slot used 
 
Freeze Store (50L Skid and Disposable Bag) 
 -50L volume 
 -Working volume 100% of max volume 
 -Needs to be mixing approved 
 -1 skid per container 
 
Final Freeze (Freeze Dryer) 
 -39.145kg sublimation capacity 
 -0.491m2 tray area 
 
6.3 Other Process Equipment 
The following is a list of process equipment that are utilized by both the upstream and 
downstream processes, but are not represented on the process flow diagram. 
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UV Cleaning System (Trojan UV Max Pro) 
 -10GPM Flow rate 
 -30mJ/cm2 dose 
 -25% efficient 
 
Peristaltic Pumps (Variable speed) 
 -Max flow 3.4LPM 
 -10% backup pumps on hand 
 
7.0 Equipment Cost Summary 
 
The following tables contain the equipment costs for both the individual units and the total units 
needed.  Costing information was obtained partially from SuperPro Designer v8.5, examining 
GE, Pall, and Sartorius’s websites, and direct contact with GE and Pall when a specific unit’s 
price was needed [34, 35].  SuperPro Designer gave an additional estimate for components that 
may have been left out in the costing.  Pumps were priced from Cole-Parmer’s website.  The UV 
treatment system was priced from excel water’s website. 
 
7.1 Process Fixed Equipment 
This section includes costing for all non-disposable components of the equipment. 
 
 
 
 
 
 
Table 10: Upstream Process Fixed Equipment 
Process Amount/Section Price (USD) Total (USD)
Wave Bioreactor 20/50 1 40,000.00$        200,000.00$        
Wave Bioreactor 100/200 1 170,000.00$     850,000.00$        
XDR Disposable Reactor - 200L 1 265,000.00$     1,325,000.00$    
XDR Disposable Reactor - 1000L 1 530,000.00$     2,650,000.00$    
Skid for Disposable Bag - 50L 3 407.00$              6,105.00$            
Skid for Disposable Bag - 1000L 1 9,000.00$          45,000.00$          
Variable Peristaltic Pump - 3.4LPM (10% Backup) 14 1,898.00$          132,860.00$        
Sterile Tube Fuser-Dry 1 20,000.00$        100,000.00$        
Unlisted Equipment (by SuperPro) 1 168,000.00$     840,000.00$        
Total Equipment Cost 6,148,965.00$    
Upstream Process
Operational Section 5
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7.2 Process Disposable Equipment 
The following is a summary of all disposable equipment based on a per batch basis.  Costs for all 
disposable equipment per year are included. 
 
 
 
Table 11: Downstream Process Fixed Equipment 
Table 12: Disposable Equipment Costs for the Upstream Process 
Process Amount/Section Price (USD) Total (USD)
Freeze Dryer - 39.15kg Sub. Capacity 1 331,000.00$     331,000.00$     
Disk Stack Centrifuge - 71.36L/hr 1 112,000.00$     112,000.00$     
Anionic Exchange Membrane 1 2,000.00$          2,000.00$          
CC700 Chromatography Column - 12.59L 1 58,000.00$        58,000.00$        
Diafilter - Area 1.85m2 1 12,627.29$        12,627.29$        
Diafilter - Area 0.09m2 1 12,627.29$        12,627.29$        
Diafilter - Area 1.22m2 1 12,627.29$        12,627.29$        
Ultra Filter - Area 0.34m2 1 12,627.29$        12,627.29$        
Sterile Filter - 10.00m2 1 25,254.58$        25,254.58$        
Depth Filter - 10.00m2 1 25,254.58$        25,254.58$        
Blending Tank - 1110L 1 198,000.00$     198,000.00$     
Skid for Disposable Bag - 50L 2 470.00$              940.00$              
Skid for Disposable Bag - 200L 5 6,847.00$          34,235.00$        
UV Cleaning System 1 2,480.00$          2,480.00$          
Variable Peristaltic Pumps - 3.4LPM (10% Backup) 15 1,898.00$          28,470.00$        
Undeffined Equipment 1 244,000.00$     244,000.00$     
Total Equipment Cost 1,112,143.32$  
Downstream Process
Operational Section 1
Operational Section 5 Batches/Section 10
Process Amount/Section/Batch Price (USD) Total (USD)
100 mL T-Flask 1 1.70$                     85.00$                
2.2L Roller Bottle 1 6.00$                     300.00$              
Culture Bag for RB - 50L 1 500.00$                25,000.00$        
Culture Bag for RB - 200L 1 2,000.00$             100,000.00$     
Culture Bag for STR - 200L 1 4,000.00$             200,000.00$     
Culture Bag for STR - 1000L 1 10,000.00$          500,000.00$     
Small Disposable Bag - 1L 1 37.00$                   1,850.00$          
Disposable Mixing Bag - 50L 3 138.00$                20,700.00$        
Disposable Mixing Bag - 1000L 1 1,600.00$             80,000.00$        
Total Disposables Cost/Year 927,935.00$     
Upstream Process
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8.0 Fixed Capital Investment Summary 
 
The following fixed capital investment summary was developed using the costing factors 
described in Biochemical Engineering and by Novais et al [20, 31].  In order to compare the two 
technologies, a costing evaluation was performed for a similar sized conventional technology 
plant.  The total capital investment is included as a reference for later sections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13: Disposable Equipment Costs for the Downstream Process 
Operational Section 1 50
Process Amount/Section/Batch Usage Price (USD) Total (USD)
Sartobind Q (AEX) - 30" 1 Single 5,680.00$    284,000.00$ 
Dft DEF Cartridge 1 Single 280.00$       14,000.00$    
Disposable Mixing Bag - 200L 3 Single 320.00$       48,000.00$    
Disposable Mixing Bag - 50L 1 Single 1,000.00$    50,000.00$    
Disposable Storage Bag - 50L 1 Single 138.00$       6,900.00$      
Disposable Storage Bag - 200L 1 Single 320.00$       16,000.00$    
Sterile Filter - 0.2 micron 1 Single 2,000.00$    100,000.00$ 
CaptoCore700 1 Multi 5,842.00$    5,842.00$      
Diafiltration Membrane 1 Multi 21,341.60$ 21,341.60$    
UF Membrane 1 Multi 663.00$       663.00$          
UV Lamp 1 Multi 245.00$       245.00$          
UV Sleeve 1 Multi 64.00$          64.00$            
Total Disposables Cost/Year 547,055.60$ 
Batches/Section
Downstream Process
Contingency Factor 1.15
Item Factor Cost
Equipment (with Utilities) 0.2 7,071,309.75$         
Piping and Installation 0.33 10,500,894.98$       
Process Control 1 13,081,923.04$       
Instrumentation 0.66 14,001,193.31$       
Electrical Power 1 8,485,571.70$         
Building Works 0.8 46,953,496.74$       
Detail Engineering 0.5 13,612,271.27$       
Construction and Site Mang. 0.75 10,606,964.63$       
Commisioning 1 2,474,958.41$         
Validation 0.5 18,738,970.84$       
Fixed Capital Investment 145,527,554.66$    
Working Capital 15% of FCI 3,478,616.09$        
Total Capital Investment 149,006,170.75$    
Disposable Technology
Table 14: Disposable Technology Fixed Capital and Total Capital Investments 
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It should be noted that the total capital and fixed capital investments of the conventional 
technology are almost double the total and fixed capital investments of the disposable 
technology.  It is also worthwhile to note that the working capital of the conventional technology 
is 10 times the working capital of the disposable technology. 
 
9.0 Safety, Health, and Environmental Considerations 
 
In the process of developing the plant that manufactures vaccines, there are a number of 
important considerations that can affect the facility.  Pathogens are a constant hazard in the 
workplace and to the product, especially when it is necessary to remove them from the product.  
Likewise, ensuring that no harmful chemicals leach into the system is also critical to the process.  
This provides a brief examination of some of the health and safety concerns of the process.  
Other safety considerations (SDS, P&ID, and HAZOP) are included in Appendices F, K, and J. 
 
9.1 Facility Layout 
The facility layout is integral to the process.  Materials have to move from one unit to another 
efficiently and quickly.  Time can be easily lost due to an improper facility layout in a process.  
Likewise, with materials moving back and forth, it is easy for pathogens and other potential 
contaminants to get into the process and create issues further down in the process stream.  One 
article provides an excellent example of a safer facility layout: 
 
 
 
Contingency Factor 1.15
Factor Conventional Tech
Equipment (with Utilities) 1 30,744,825.00$       
Piping and Installation 0.9 31,820,893.88$       
Process Control 0.37 13,081,923.04$       
Instrumentation 0.6 21,213,929.25$       
Electrical Power 0.24 8,485,571.70$          
Building Works 1.66 58,691,870.93$       
Detail Engineering 0.77 27,224,542.54$       
Construction and Site Mang. 0.4 14,142,619.50$       
Commisioning 0.07 2,474,958.41$          
Validation 1.06 37,477,941.68$       
Fixed Capital Investment 245,359,075.91$    
Working Capital 15% of FCI 36,803,861.39$       
Total Capital Investment 282,162,937.30$    
Conventional Technology
Table 15: Conventional Technology Fixed Capital and Total Capital Investments 
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The layout of this facility shows a type of modular design.  Each section of the process 
(inoculation, culturing, purification, etc.) has its own separate stage and room in the process.  
Also, corridors in the top, middle, and bottom of the facility layout allow for movement between 
stages and areas of the facility. 
 
Safety and health concerns are minimized by using this type of layout.  While the entire facility 
is BSL-2, certain areas are Class D (capturing, cultivation, purification), while other portions are 
Class C sections of the facility (inoculum and final purification), allowing for better separation 
from processes where high contamination is a risk [36]. 
 
In the Class D sections of the facility, the primary portions of the downstream process and 
cultivation occur.  This facility layout allows for direct access between each downstream process 
and prevents exposure of the product to other areas of the plant by having common corridors 
between them.  This also allows for segregation of the process, should one of the parts of the 
process become contaminated.  The added corridors allow for personnel to move in a contained 
environment, without having to de-gown and exit the secure portions of the facility.  This means 
individuals can move easily from one area to another.  The risk of outside contaminants entering 
with the individual is also reduced, as they are kept within the controlled environment. 
 
The Class C sections are for the health and safety of the workers in the plant, while maintaining 
product purity.  These sections can be held to more stringent standards.  The reason is that the 
Class C portions of the facility are where the final processes and the inoculation steps that place.  
It is critical to prevent the baculovirus from escaping to other parts of the facility and infecting 
the cultivation tanks, prior to the desired infection time.  Likewise, proper cleaning methods are 
Figure 3: Theoretical Single Use Facility Layout from Vaccine Manufacturing in the Coming 
Decade [36]. 
28 
 
more strictly enforced here, as individuals carrying the virus on them could unintentionally 
release the baculovirus into the public and infect arthropods [9], damaging the food chain.  Thus, 
there is also an environmental concern in ensuring that this part of the facility is stringently 
controlled. 
 
Keeping outside pathogens and other materials out of the final packaging steps is also necessary.  
Until the package from the freeze dryer is sealed, it is desirable to isolate this part of the process 
from the outer areas of the plant.  This part of the process occurs in the final formulation section 
of the plant labelled above.  The actual product, once sealed, is safe to move and transport to 
other facilities, but until then, this part of the process must be isolated to prevent contamination. 
 
9.2 Infection of the Staff 
As stated earlier, the baculovirus expression system is not contagious to humans.  The 
baculovirus expresses the hemagglutinin antigen that is similar to the influenza virus, but is not 
the influenza virus itself [7, 8, 9].  Thus, the potential for the staff at the facility to become 
infected is eliminated due to the selection of the cell line for the process. 
 
There is a concern, though, of other pathogens entering the system.  If one of the staff were to 
enter the facility while ill, they could potentially introduce an undesired pathogen into the 
processing system.  There is no prevention for a potential infection entering the system, for 
reasons discussed in the next subsection, thus it would be very easy for other pathogens to enter 
and contaminate a batch.  Individuals in the facility will be required to wear proper PPE (such as 
masks, gloves, gowns, facial protection, closed shoes/boots, etc.), but will also be 
encouraged/required to stay home should they become ill, or suspect they have become ill.  This 
will reduce the potential for disease to enter the system. 
 
9.3 Chemical Safety 
Traditional processes use chemicals such as β-propiolactone, benzonase, and formalin in their 
processes.  Similarly, some sources recommend the use of antibiotics when growing cellular 
cultures.  These steps, though, are eliminated in the overall process due to their inherent risk in 
terms of safety for those who work with them and for the health of the people who receive the 
vaccine. 
 
Looking at antibiotics, it is recommended that they are not used for processing.  Some 
antibiotics, if improperly removed, can remain in the product.  When distributed, these 
antibiotics can potentially cause a reaction in consumers.  Secondly, antibiotics have been 
determined to be ineffective at eliminating pathogens that contaminate the product.  According to 
the literature, pathogens are merely masked by antibiotics, rather than eliminated [9].  Thus, 
antibiotics were removed from the process for the health of those downstream due to the 
potential for contamination from either improperly removed antibiotics or masked pathogens. 
 
The need for an inactivation step was eliminated due to the choice of insect cell lines for 
processing.  Thus, traditional inactivation chemicals β-propiolactone and formalin were 
eliminated from the process.  Both of these chemicals pose severe health hazards to workers and 
consumers.  β-propiolactone is a suspected carcinogen, highly flammable, and can vaporize into 
either hazardous components or lead to tank ruptures [37].  Formalin is a mix of methanol, water, 
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and formaldehyde.  Due to its composition, it is a Class 4 flammable and Class 3 health hazard, 
according to its NFPA code [38].  Both of these pose health hazards to workers as they can be 
vaporized and inhaled while processing, creating a potential health hazard.  Factoring in their 
flammability, and it becomes clear that both of these components should be eliminated if 
possible.  Lastly, if these components were improperly removed, they would potentially be 
injected into consumers down the product line.  Thus, for the safety and health of both 
consumers and employees, these components were deemed unnecessary and eliminated. 
 
Benzonase, unlike the other components, does not pose a major health hazard according to its 
MSDS.  It is primarily used for the removal of hcDNA from the process.  It does contain 
glycerol, which requires proper protection (such as eye and skin protection equipment), but it is 
otherwise non-hazardous [39].  Following the principles of green engineering, if a chemical can 
be eliminated, it should [14].  Benzonase cannot continue into the final product, as the glycerol 
could be a potential hazard to consumers if injected.  Thus, by using physical means to remove 
the hcDNA, a benzonase treatment is eliminated from the process as well. 
 
Strong acids and bases are used in the chromatography and membrane unit of the process.  
Special provisions have to be made in order to ensure the safety of employees when working 
with these chemicals.  Neutralizing agents and face/body wash stations will be in each major 
room, in order to ensure that employees have the necessary means to neutralize and remove acids 
and bases if they are spilled.  Further discussion of these chemicals is in Appendix F. 
 
9.4 Testing and Data Logs 
In order to ensure that the product is safe for injection into humans, frequent testing of the cells 
during their growth phase is required.  The World Health Organization (WHO) has outlines for 
what is the proper method for certifying a batch/production line of vaccines before final 
distribution into the public [12].  Examples of these tests are as follows: 
 
1. Identity Tests- Used to determine that the hemagglutinin is of the same type as the 
influenza virus for that season. 
2. Sterility Test- Ensures that no other pathogens are contained within the lot. 
3. Hemagglutinin Content- The WHO requires at least 12µg of each strain per dose.  Most 
vaccines contain 15µg/strain/dose. 
4. General Safety- Lots need to be tested to ensure that no toxins are present in the batch. 
5. Endotoxin- Tests to ensure that no endotoxins are contained in the batch. 
6. Visual Integrity- Any abnormal units should be discard. 
7. Records- Proper records of processing of each batch should be kept.  Improper records 
can result in the discarding of a batch. 
8. Retained Samples- As part of Good Manufacturing Practices (GMP), samples of each lot 
should be retained for quality assurance purposes. 
9. Labelling- The WHO outlines what information should be affixed to each carton of 
vaccines. 
10. Transportation- Transportation should follow standard GMPs. 
11. Stability- Vaccines should be studies to ensure that they are stable with time, and lack 
degradation during their expected lifespan 
12. Storage Conditions- Vaccines should be stored between 2°C to 8°C. 
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13. Expiration Date- An expiration date for a vaccine should be affixed to the vaccines, and 
should be approved by proper authorities. 
 
These are some of the guidelines outlined by the WHO.  A sample of information that should be 
recorded, as outlined by the WHO, is given in Appendices H and I. 
 
10.0 Other Important Considerations 
 
There were other considerations that were requested by management or considered important to 
the project.  This section discusses these considerations. 
 
10.1 Costing and Prices 
An attempt was made to accurately cost all equipment for the overall process.  The reason is that 
economic data was then produced using multiplying factors provided by Novais et al [20] and 
Biochemical Engineering [31].  This included items, such as HEPA Vacuum utilities, that could 
not be easily quantified. 
 
SuperPro Designer v8.5 was the initial program that was used for costing.  This produced a list 
of all of the disposable and fixed equipment used in the process, along with usages and 
approximate cost data.  When the initial economic analysis was performed, though, the economic 
data appeared too favorable to be considered reliable. 
 
From here, manufacturing websites were visited in order to obtain up to date prices.  This 
included visiting Pall [40], GE [41], Cole-Parmer [42], Sartorius [43], Icis [44], ATCC [45], 
Sigma-Aldrich [46], excel water [47], PCI-Scientific [48], and Alibaba (1 item) [49] websites 
over the course of the entire project.  Some data for items such as Water for Injection (WFI) and 
tap water were provided by the American Institute for Chemical Engineers and used in the 
economic analysis, as requested by management. 
 
Websites did not provide all of the relevant equipment data, though, and suppliers had to be 
contacted for specific items.  GE [34] and Pall [35] were available for direct contact, and 
provided specific item data in order to improve the economic analysis.  At the end of the process, 
only 3 items were left to the SuperPro Designer v8.5 economic analysis.  SuperPro Designer v8.5 
added an additional factor for unspecified equipment.  For the scope of this project, that factor 
can include: tubing, fittings, wheel-blocks for rolling components, and any other unforeseen 
expenditures in the process. 
 
Another important consideration was time to market.  The comparison between the production 
time of a conventional facility and a disposable facility was 21 years of production.  However, 
relevant data indicated that a disposable facility would be validated in under 2 years, while a 
conventional facility would take at least 4 years for validation [19].  Thus, a disposable facility 
was considered to have a project time line of 23 years, while a conventional had a timeline of 25 
years in their respective evaluations.  This turned out to play a critical role in the economic scope 
of the project, as is discussed in section 12 of the report. 
 
 
31 
 
10.2 Scheduling 
One of the requirements for the cell based process is that it can produce vaccines as quickly as an 
egg-based process.  Based on cellular data provided, it was determined that the production 
process for influenza vaccines using this technology is faster than egg-based technology of a 
similar size.  One of the fastest producers is GSK with 21 million doses in 6 months [24].  The 
project had to produce 22 million doses in 6 months in order to be competitive. 
 
The upstream process takes the longest time with 522.21 hours for producing a single batch, 
while the downstream process takes 74.8 hours to fully process a single batch.  In the upstream 
process, the bottleneck and longest process is the Production STR with 152.32 hours, while the 
downstream bottleneck and longest process is the Freeze Dryer at 26 hours.  This result indicates 
that each upstream unit can start a new batch every 152.32 hours. 
 
In order to optimize the system, the ideal number of upstream processing units to downstream 
processing units was determined to be 5:1.  Based on the time to process downstream, it was 
determined that the upstream process could not have more than 5 units (152.32hours/26hours = 
5.86 units, which rounds down to 5).  The following table shows the time to produce 22 million 
doses when compared to the number of upstream sections: 
 
 
 
 
 
 
 
 
 
 
 
As can be seen by the data above, the law of diminishing returns in terms of saved time becomes 
apparent.  Using 2 processing sections yields a time just under 6 months, which for the pandemic 
consideration, means that 2 units was not ideal.  3 upstream sections was considered to take too 
long, as 1 month must be added for the time it takes to research and develop the baculovirus 
strain, causing this system to take almost 5.5 months.  The final decision was to maximize the 
process and use 5 sections.  The reason for this decision is that this maximizes the potential for 
production during a pandemic situation, which is discussed in the next subsection. 
 
The result is that a 4 or 5 section upstream process must be utilized, which is narrowed to a 5 
section upstream process in the next subsection.  Scheduling allows regular production of the 
vaccine to have the entire product line out before any other supplier on the market (114 days, 
factoring in 1 month for baculovirus development).  This ensures that all of the product makes it 
to consumers, as consumers will purchase vaccines produced by this facility before the other 
producers have time to put their product on the market, essentially having a temporary monopoly 
on the market.  The first batch is ready in 21 days, allowing for rapid validation of the product in 
terms of time. 
 
Upstream Sections Total Process Time (days)
1 332.7
2 177.3
3 125.4
4 99.5
5 84.0
Table 16: Total Processing Time as a Function of Upstream Sections 
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10.3 Pandemic Considerations 
As stated above, another consideration that came into scheduling was a pandemic situation.  
During a pandemic, the demand for influenza vaccine significantly increases.  This is seen in the 
following figure: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As can be seen above, there is a spike in the 2010/2011 season, when there was a suspected 
pandemic flu season.  This lead to a spike in the amount of flu vaccine for that year of 163 
million doses.  That number quickly tapered off to 134.5 million doses in the 2013/2014 season 
[1].  Before that, the annual consumption was around 100 million or less per year [3].  This 
means that the doses consumed each season fluctuate positively and negatively.  This shows, 
though, that there is a need for a facility that can quickly and effectively increase or decrease 
production, while still being competitive with other producers, especially during a pandemic. 
 
In terms of a pandemic, a facility needs to produce as many vaccines as possible.  The reason is 
that during a pandemic, the market is nearly insatiable when it comes to demand.  Looking at the 
following table shows how having the various number of upstream sections can affect overall 
production over 8 months: 
 
In this situation, it is clear that a 5 section upstream process is the most ideal.  The extra unit 
adds roughly 10 million extra doses in an 8 month time frame.  This can add up to $67.5 million 
Figure 4: Vaccines Consumed per Season [1, 2, 3] 
Upstream Sections Total Process Time (days) Doses Per Month Doses in 8 Month Pandemic
1 332.7 1,983,498              15,867,987                                   
2 177.3 3,723,511              29,788,084                                   
3 125.4 5,262,278              42,098,223                                   
4 99.5 6,632,805              53,062,438                                   
5 84.0 7,861,253              62,890,023                                   
Table 17: Pandemic 8 Month Dose Production as a Function of Upstream Sections 
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dollars in terms of sales at current market prices, over a smaller 4 section upstream process [50].  
Thus, it can be inferred that ideally, a 5th upstream section is worth the capital investment for the 
extra ability to produce when the market demand increases significantly. 
 
10.4 Storage and Final Formulation/Filling 
The final consideration for the overall project is the storage.  After the freeze drying process, the 
powdered vaccine subunit is stored in a vacuum sealed 10L bag before being shipped.  The 
storage area containing the vaccine is to be held at 4°C, which is in line with the guidelines by 
the WHO [12], though, the vaccine is stable at temperatures of up to 20°C [30].   This will 
ensure that the vaccine subunit is properly stored in a conducive climate before being sent for 
final formulation and filling, while ensuring that minimal amounts of the vaccine degrade.  The 
inulin sugar matrix helps to stabilize the hemagglutinin and prevent damage to the antigen during 
transport as well [29]. 
 
In the final formulation and filling step, the three subunits of the vaccine are combined into a 
single trivalent vaccine unit.  This is then hydrated into a phosphate buffered saline solution of 
20mM sodium phosphate buffer and roughly 0.7M NaCl in solution.  In order to do this, some 
extra sodium phosphate buffer will need to be added to the solution to increase the molarity.  The 
vaccines can be stored/shipped in 5mL bottles.  The volumetric amount per dose is 0.5mL, 
meaning that each bottle would contain 10 doses. 
 
Further research is necessary as to whether or not the vaccine should be preservative free or not.  
Vaccines with preservatives in them sell at a lower price, and were used for the economics 
portion of this cost comparison [50].  The reason is that the preservative, thimerosal, is a 
mercuric compound.  The addition of a preservative can limit the market, due to stigmas against 
them.  The vaccine can be distributed to younger age groups if it lacks preservative.  These two 
reasons mean that investigating the possibility of a preservative free vaccine is worthwhile.  
 
11.0 Manufacturing Costs 
 
The following tables are the itemized manufacturing costs of the process described in the report.  
The itemized utilities requirements are summarized in section 4, Tables 5-7.  Total product costs 
are included, as well, for the economic section of the report. 
 
11.1 Materials Costs 
The following tables show the material usage and costs of the described process. 
 
 
5 Batches/Section 10
Material /Section/Batch Units Price (USD)/Unit Total (USD)
Inoculation Media 1 mL 431.00$                 431.00$                                         
Purified Air 382.966 kg -$                        -$                                                
Media Powder 30.7692 kg 974.03$                 1,498,500.00$                             
Water For Injection 999 L 1.00$                      49,950.00$                                   
Sodium Bicarbonate 0.349 kg 0.20$                      3.49$                                              
Total Material Price 1,548,884.49$                             
Operational Section
Upstream Process
Table 18: Upstream Materials Costs 
34 
 
 
 
 
 
11.2 Disposables Costs 
Tables 12 and 13 of section 7 summarize these costs.  They are considered to be a part of the 
operational cost of the process, and are accounted for as the Total Materials Cost in Table 20. 
 
11.3 Total Manufacturing Costs 
For the economic comparison in section 12, the manufacturing costs of both a conventional 
process and a disposable process were calculated using factors in Novais et al [20] and 
Bioprocess Engineering [31].  These tables are later used in the full economic comparison. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Batches/Section 50
Material /Section/Batch Units Price (USD)/Unit Total (USD)
Hydrochloric Acid (1M) 2.7 L 26.40$                    3,564.00$      
Inulin 8.5 kg 20.00$                    8,500.00$      
Isopropanol 2.637 kg 4.87$                      642.56$          
Sodium Dibase Phosphate (anhy) 0.737 kg 2.05$                      75.48$            
Sodium Mobase Phosphate (anhy) 0.182 kg 2.17$                      19.76$            
Sodium Chloride 9.707 kg 0.15$                      72.80$            
Sodium Hydroxide 0.435 kg 21.80$                    474.08$          
Water 10660 kg 0.54$                      289,426.25$ 
Water For Injection 592 L 1.00$                      29,602.70$    
Total Material Price 332,377.62$ 
Downstream Process
Operational Section
Table 19: Downstream Materials Costs 
Item Factor Costs
Total Materials Cost 16 3,356,252.71$         
Labor Costs 1 489,453.52$             
Utilities 0.5 244,726.76$             
Depreciation (Estimate not used) 0.6 398,555.01$             
Other (Royalties, Licensure, etc) 1 1,643,165.39$         
Equipment Amortization 12% Int. over 10 years 1,256,531.25$         
Building Amortization 12% Int. over 30 years 5,801,558.58$         
Land Tax and Insurance 4% of Fixed Capital 5,821,102.19$         
Plant Overhead 25% of Labor Costs 122,363.38$             
Manufacturing Costs 18,735,153.77$       
General Expenses 11.55% of Sales 17,189,865.00$       
Total Product Cost 35,925,018.77$      
Total Product Cost 1st Year 33,879,802.28$      
Disposable Technology
Table 20: Total Manufacturing and Product Costs of Disposable Technology 
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It should be noted that despite the disposable technology using more materials than the 
conventional technology, the conventional technology still has almost $10 million more in 
manufacturing costs.  The manufacturing costs are all of the operational costs or the total product 
cost minus general expenses. 
 
12.0 Economic Analysis 
 
Two distinct economic analyses were requested.  The first analysis requested was the price of the 
influenza vaccine with a discrete IRR of 25%.  The second analysis was the economic value at 
current market prices.  Revenue was based on 50% of the doses being sold in the private 
sector/smaller customers and 50% of the doses being sold in the public sector/larger customers, 
which is normal for most vaccine manufacturers [3].  Prices calculated reflect the actual market 
price before a $0.75/dose excise tax is assessed against the dose. 
 
12.1 Price with an Internal Rate of Return of 25% 
The following tables summarize the economics of a disposable plant design and a conventional 
plant of similar size based on an internal rate of return of 25%: 
 
 
 
 
 
 
 
 
Item Factor Cost
Total Materials Cost 0.06 209,765.79$             
Labor Costs 0.14 489,453.52$             
Utilities 0.14 489,453.52$             
Depreciation (Estimate not used) 0.19 664,258.35$             
Other (Royalties, Licensure, etc) 0.47 1,643,165.39$          
Equipment Amortization 12% Int. over 10 years 5,320,376.95$          
Building Amortization 12% Int. over 30 years 7,251,948.22$          
Land Tax and Insurance 4% of Fixed Capital 9,814,363.04$          
Plant Overhead 25% of Labor Costs 122,363.38$             
Manufacturing 25,340,889.81$       
General Expenses 11.55% of Sales 17,189,865.00$       
Total Product Cost 42,530,754.81$       
Total Product Cost 1st Year 41,936,418.40$       
Conventional Technology
Table 21: Total Manufacturing and Product Costs of Conventional Technology 
Table 22: Economics of Disposable Technology with an IRR of 25% 
Public Price 3.78$                                               
Private Price 7.04$                                               
Payback Period 4.26 Years
Rate of Return 22.84%
Avg. Annual Net 37,279,362.59$                            
Economics of Disposable Technology at an IRR of 25%
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The production lifespan of each plant was 21 years, with the first year only producing half of the 
anticipated product.  However, the total project life was slightly different for each plant.  The 
conventional facility was estimated to take 4 years to build, while the disposable facility took 
only 2 years.  According to the literature, this is the normal construction time frame for each of 
these facilities, as a conventional plant takes a longer time to design, commission, qualify, and 
validate [19]. 
 
In this comparison, the key points are the prices.  The vaccines that are being produced are 
trivalent influenza vaccines, and it was assumed that there would be some level of preservative in 
each dose.  Thus, the most economically unfavorable view is given for each case.  By 
comparison, current manufacture GSK sells the lowest price trivalent influenza vaccine, Flulaval 
Trivalent, which is egg based and contains a preservative [51].  The price is $7.65/dose in private 
sale and $5.88/dose in public sale [50]. 
 
Based on these prices, the disposable technology is clearly competitive.  By producing at a price 
below the competition, it can be almost assured that nearly all of the vaccines will be sold.  By 
producing at a lower price than the cheapest egg based competition, the economics are clearly 
favorable for disposable technology.  A rate of return in the 20 percent range with a payback 
period just over 4 years means that this project is easily viable at these prices. 
 
The conventional technology paints a grimmer picture, by comparison.  The average net earnings 
is three times that of the disposable technology, and the short payback period and rate of return 
make it deceivingly appear like the more favorable option.  The prices, though, are higher than 
the highest egg based trivalent vaccine with preservative, Fluzone, at a price of $8.153/dose in 
the public sector and $10.69/dose in the private sector in a 10 dose vial [50].  This makes the 
conventional technology option significantly less competitive in the current market, adding a 
clear strike against using this technology. 
 
12.2 Economics at Current Prices 
The final comparison looks at the technology at current prices.  The prices used for this portion 
were the GSK vaccine prices stated earlier of $7.65/dose private and $5.88/dose public [50].  
This is currently the cheapest influenza vaccine price on the market.  Thus, it was considered to 
give the most economically unfavorable view of both technologies (worst case scenario), while 
showing the competitiveness of a disposable technology facility design in the current economic 
market.  Again, the expected plant lives referenced in the previous subsection are used for the 
IRR and NPV calculations. 
Table 23: Economics of Conventional Technology with an IRR of 25% 
Public Price 8.24$                              
Private Price 11.50$                            
Payback Period 3.18 Years
Rate of Return 27.58%
Avg. Annual Net 92,655,938.68$           
Economics of Conventional Technology at an IRR of 25%
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Using the lowest market prices for an egg based vaccine with preservative, the economic 
analysis becomes more realistic.  According Biochemical Engineering, an expected nominal 
interest rate is 12% for a recombinant protein plant [31].  Thus, this was used for the present 
value and net present value calculations. 
 
At current market prices, the payback period becomes less than 3 years and the return on 
investment goes into the mid 30 percent range.  The average net earnings show a reasonable rate 
of $56 million net earnings each year.  The IRR and the NPV show that the project is worth 
going ahead.  For an investment of $149 million, the NPV is $277 million.  A NPV higher than 
the actual investment indicates that the project would add more than the value of the investment 
to the company’s value, thus meaning that the project should go forward because the company 
would be significantly more valuable than its initial investment. 
 
When looking at the discrete IRR of 33%, Peters and Timmerhaus state that this is reflective of a 
“new product or process in a new application” [52].  This evaluation is somewhat accurate of the 
technology.  While the product is not “new,” it is made in a new way and uses a new type of 
technology to produce it.  The minimum for this category is 24%, according to Peters and 
Timmerhaus, which means that this process is well within in the needed IRR value range for this 
type of process.  Thus, the IRR is reflective of the process and, again, indicates that the plant 
design is economically favorable. 
 
The conventional technology plant gives a different look.  The payback period is increase to 6 
years and the return on investment is lower at just under 15%.  The average net annual earnings 
are almost $6 million less at $49 million.  The present value gives an even worse look at 
conventional technology.  With an investment of $282 million, the NPV is only $90 million.  
Net Present Value 277,875,122.75$            
Payback Period 2.83 years
Return on Investment 34.42%
IRR/DCFROR 33.36%
Average Net Earnings 56,174,153.52$              
Disposable Technology at Current Prices and 12% Interest
Table 24: Economics of a Disposable Plant at Current Prices 
Net Present Value 90,488,506.37$             
Payback Period 6.03 years
Return on Investment 14.66%
IRR/DCFROR 16.42%
Average Net Earnings 49,251,948.44$             
Conventional Technology at Current Prices and 12% Interest
Table 25: Economics of a Conventional Plant at Current Prices 
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While this is positive, it indicates that the project returns less of an increase in value to the 
company, while using a higher investment than the disposable technology. 
 
The discrete IRR given is very modest at 16.4%.  According to Peters and Timmerhaus this is a 
“new product entering into established market, or a new technology” [52].  While the plant uses 
conventional technology, the process is new using insect cell lines, thus fitting into this category.  
It should be noted, though, that for this category, the minimum is 16%, according to Peters and 
Timmerhaus [52].  This means that the conventional technology option barely meets the criteria 
for this category, and may not stand up to a more rigorous economic analysis.  The added lower 
NPV ultimately shows that using conventional technology for this process is not as sound of an 
investment. 
 
12.3 Economic Concluding Remarks 
It is clear from the analyses above that the disposable technology is the most economically viable 
option.  At a 25% IRR, the product price is competitive with the cheapest product on the market, 
while the conventional option is not competitive with any product.  At a 12% interest rate and 
current prices, it is clear that an investment in a disposable technology process would be a more 
sound investment over conventional technology, according to the NPV. 
 
13.0 Conclusions and Recommendations 
 
It is recommended that the company invest in a process that produces trivalent influenza 
vaccines using an insect cell baculovirus expression system.  Using disposable technology 
instead of conventional technology, the overall process will yield a higher value added to the 
company, with a lower investment.  The design recommended in this report uses physical means 
of treating the product and eliminates the need to use harmful chemicals in the process, thereby 
increasing its safety. 
 
It is recommended that further investigation be performed in order to determine if the addition of 
a preservative is necessary.  A preservative free vaccine would reduce potential downstream 
materials costs, while increasing the value of the product.  Increasing the plant size or 
operational time should be considered as well.  While the production for the plant is set at a 
medium sized facility with 22 million doses a year, a larger facility would be able to produce 
more in the same amount of time or using the same technology would produce more in a slightly 
longer season.  The results would yield higher profits for the company, but the increased 
production could potentially flood the market. 
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Appendix A: Mass and Energy Streams 
 
The follow appendix contains the individual and total mass and the energy of all the streams 
based on the process flow diagrams. 
 
A-1: Upstream Streams 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time Ref: Batch VialCells Air1 Media1-1 Vent1 Media Store 1 Air2 S-102 Media 2-1
Type Raw Material Raw Material Raw Material Emission Raw Material Raw Material
Total Flow g 1 0.1474 18.9337 0.1486 697.2292 1.1792 19.9337 90.3609
Temperature °C 25 25 25 25 25 25 27 25
Pressure bar 1.013 1.013 1.013 1.013 1.013 1.013 1.263 3.377
Liq/Sol Vol Flow L 0.001 0 0.019 0 0.7 0 0.02 0.0907
Total Enthalpy kJ 0.1013 0.0037 1.9209 0.0038 70.7384 0.0298 2.184 9.1677
Total Contents g 1 0.1474 18.9337 0.1486 697.2292 1.1792 19.9337 90.3609
Ammonium 0 0 0 0 0 0 0 0
Carb. Dioxide 0 0 0 0 0 0 0 0
Cell Biomass 0 0 0 0 0 0 0.0111 0
Glucose 0 0 0.1136 0 4.1834 0 0.1134 0.5422
Haemagglutinin 0 0 0 0 0 0 0 0
KCl 0 0 0 0 0 0 0 0
KH2PO4 0 0 0 0 0 0 0 0
L-Glutamine 0 0 0.0189 0 0.6972 0 0.0188 0.0904
Lactate 0 0 0 0 0 0 0.0001 0
Media 0.0299 0 0.4506 0 16.5941 0 0.4696 2.1506
Na2HPO4 0 0 0 0 0 0 0 0
NaH2PO4 0 0 0 0 0 0 0 0
NaHCO3 0 0 0.0066 0 0.244 0 0.0066 0.0316
Nitrogen 0 0.1131 0 0.114 0 0.9046 0 0
Oxygen 0 0.0343 0 0.0346 0 0.2746 0 0
Sodium Chloride 0 0 0 0 0 0 0 0
Water 0 0 0 0 0 0 0 0
WFI 0.9701 0 18.3439 0 675.5105 0 19.314 87.5462
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Time Ref: Batch Media 2-2 Vent2 S-101 Media Store 2 Air3 Media 3-1 Media 3-2 Vent3 S-107
Type Emission Raw Material Raw Material
Total Flow g 500.238 0 610.5316 18148.4611 25.9429 2768.9959 14780.2624 0 9079.8798
Temperature °C 25 25 27 25 25 25 25 25 27
Pressure bar 2.593 1.013 2.058 1.013 1.013 1.594 1.466 1.013 1.797
Liq/Sol Vol Flow L 0.5022 0 0.6134 18.212 0 2.78 14.839 0 9.1227
Total Enthalpy kJ 50.7524 0 66.8975 1841.2783 0.6567 280.9325 1499.5528 0 994.9084
Total Contents g 500.238 0 610.5316 18148.4611 25.9429 2768.9959 14780.2624 0 9079.8798
Ammonium 0 0 0 0 0 0 0 0 0
Carb. Dioxide 0 0 0 0 0 0 0 0 0
Cell Biomass 0 0 0.3394 0 0 0 0 0 5.0455
Glucose 3.0014 0 3.6521 108.8908 0 16.614 88.6816 0 54.4006
Haemagglutinin 0 0 0 0 0 0 0 0 0
KCl 0 0 0 0 0 0 0 0 0
KH2PO4 0 0 0 0 0 0 0 0 0
L-Glutamine 0.5002 0 0.6054 18.1485 0 2.769 14.7803 0 9.0179
Lactate 0 0 0.0025 0 0 0 0 0 0.0375
Media 11.9057 0 14.2031 431.9334 0 65.9021 351.7702 0 211.1432
Na2HPO4 0 0 0 0 0 0 0 0 0
NaH2PO4 0 0 0 0 0 0 0 0 0
NaHCO3 0.1751 0 0.2133 6.352 0 0.9691 5.1731 0 3.1778
Nitrogen 0 0 0 0 19.9012 0 0 0 0
Oxygen 0 0 0 0 6.0416 0 0 0 0
Sodium Chloride 0 0 0 0 0 0 0 0 0
Water 0 0 0 0 0 0 0 0 0
WFI 484.6556 0 591.5158 17583.1365 0 2682.7416 14319.8572 0 8797.0573
Time Ref: Batch Infection Media for Infection S-108 S-103 Media Store 3 Air4 Media 4-1 Vent4
Type Raw Material Raw Material Raw Material Raw Material Emission
Total Flow g 1 40657.655 40657.655 9079.8798 41853.4684 366.2936 41178.3549 427.6984
Temperature °C 25 25 25 27 25 25 25 27
Pressure bar 1.013 1.013 5.518 2.313 1.013 1.013 6.349 1.013
Liq/Sol Vol Flow L 0.001 40.8 40.8192 9.1227 42 0 41.342 0
Total Enthalpy kJ 0.1013 4124.9811 4124.9811 994.9084 4246.304 9.2715 4177.8094 11.7322
Total Contents g 1 40657.655 40657.655 9079.8798 41853.4684 366.2936 41178.3549 427.6984
Ammonium 0 0 0 0 0 0 0 0.0212
Carb. Dioxide 0 0 0 0 0 0 0 0.0516
Cell Biomass 0 0 0 5.0455 0 0 0 0
Glucose 0 243.9459 243.9459 54.4006 251.1208 0 247.0701 0
Haemagglutinin 0 0 0 0 0 0 0 0
KCl 0 0 0 0 0 0 0 0
KH2PO4 0 0 0 0 0 0 0 0
L-Glutamine 0 40.6577 40.6577 9.0179 41.8535 0 41.1784 0
Lactate 0 0 0 0.0375 0 0 0 0
Media 0.0299 967.6522 967.6522 211.1432 996.1125 0 980.0448 0
Na2HPO4 0 0 0 0 0 0 0 0
NaH2PO4 0 0 0 0 0 0 0 0
NaHCO3 0 14.2302 14.2302 3.1778 14.6487 0 14.4124 0
Nitrogen 0 0 0 0 0 280.9904 0 328.068
Oxygen 0 0 0 0 0 85.3032 0 99.5576
Sodium Chloride 0 0 0 0 0 0 0 0
Water 0 0 0 0 0 0 0 0
WFI 0.9701 39391.1691 39391.1691 8797.0573 40549.7329 0 39895.6491 0
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Time Ref: Batch S-104 Media Store 4 Air5 Media 5-1 Media 5-2 S-109 Vent5 To Downstream
Type Raw Material Raw Material Emission
Total Flow g 50258.1636 895933.2819 382572.4037 227598.5106 666775.1974 49738.5348 383754.2436 994368.7116
Temperature °C 27 25 25 25 25 4 27 27
Pressure bar 1.013 1.013 1.013 10.081 3.08 1.867 1.013 1.013
Liq/Sol Vol Flow L 50.4951 899.07 0 228.503 669.425 49.5539 0 999.0553
Total Enthalpy kJ 5506.9311 90898.2039 9683.5124 23091.3353 67648.6398 807.407 10492.3423 108955.8303
Total Contents g 50258.1636 895933.2819 382572.4037 227598.5106 666775.1974 49738.5348 383754.2436 994368.7116
Ammonium 0 0 0 0 0 0 0.8185 0
Carb. Dioxide 0 0 0 0 0 0 1.997 0
Cell Biomass 27.9625 0 0 0 0 5.0455 0 554.0401
Glucose 301.1267 5375.5997 0 1365.5911 4000.6512 298.3465 0 5957.5154
Haemagglutinin 0 0 0 0 0 0 0 25.1654
KCl 0 0 0 0 0 0 0 0
KH2PO4 0 0 0 0 0 0 0 0
L-Glutamine 49.9172 895.9333 0 227.5985 666.7752 49.6756 0 987.3145
Lactate 0.2076 0 0 0 0 0.0375 0 4.2992
Media 1168.653 21323.2121 0 5416.8446 15869.2497 1178.8253 0 23096.4782
Na2HPO4 0 0 0 0 0 0 0 0
NaH2PO4 0 0 0 0 0 0 0 0
NaHCO3 17.5902 313.5766 0 79.6595 233.3713 17.408 0 348.029
Nitrogen 0 0 293478.1297 0 0 0 294383.6942 0
Oxygen 0 0 89094.274 0 0 0 89367.7339 0
Sodium Chloride 0 0 0 0 0 0 0 0
Water 0 0 0 0 0 0 0 0
WFI 48692.7065 868024.9602 0 220508.8169 646005.15 48189.1965 0 963395.8699
Time Ref: Batch RBR Store Res. 50L Store Res. Inf. Med. Res. 100L Store Res. 1000L Store Res. Energy In By Pumps Energy Lost to Surr.
Type
Total Flow g
Temperature °C
Pressure bar
Liq/Sol Vol Flow L
Total Enthalpy kJ 10.8183 60.793 0 68.4946 158.2288 91800 82918.86
Total Contents g 106.6303 599.2028 0 675.1135 1559.5739
Ammonium 0 0 0 0 0
Carb. Dioxide 0 0 0 0 0
Cell Biomass 0 0 0 0 0
Glucose 0.6398 3.5952 0 4.0507 9.3574
Haemagglutinin 0 0 0 0 0
KCl 0 0 0 0 0
KH2PO4 0 0 0 0 0
L-Glutamine 0.1066 0.5992 0 0.6751 1.5596
Lactate 0 0 0 0 0
Media 2.5378 14.2611 0 16.0677 37.1178
Na2HPO4 0 0 0 0 0
NaH2PO4 0 0 0 0 0
NaHCO3 0.0373 0.2098 0 0.2363 0.5458
Nitrogen 0 0 0 0 0
Oxygen 0 0 0 0 0
Sodium Chloride 0 0 0 0 0
Water 0 0 0 0 0
WFI 103.3087 580.5377 0 654.0838 1510.9933
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A-2: Downstream Streams 
 
 
 
 
Time Ref: Batch From Upstream S-113 To WM (1) S-114 AEB Buffer S-116 To WM (2) S-117 S-122
Type Raw Material Raw Material
Total Flow kg 994.3687 994.3687 990.6014 3.7673 130.7544 134.5218 1.0969 133.4249 133.4249
Temperature °C 27 27 42 42 25 25.41 25.41 25.41 25.41
Pressure bar 1.013 10.2 1.013 1.013 1.013 3.011 1.013 3.011 2.963
Liq/Sol Vol Flow L 999.0553 999.0551 1000.7901 3.8054 126.502 132.5958 1.0919 131.504 131.504
Total Enthalpy kJ 111555.6295 111552.9738 172969.4596 558.8638 13417.1592 13975.9258 57.8666 13918.0592 13917.9604
Total Contents g 994368.7116 994368.7116 990601.3671 3767.3445 130754.41 134521.7545 1096.866 133424.8885 133424.8885
Ammonium 0 0 0 0 0 0 0 0 0
Carb. Dioxide 0 0 0 0 0 0 0 0 0
Cell Biomass 554.0401 554.0401 11.0808 542.9593 0 542.9593 542.9593 0 0
Glucose 5957.5154 5957.5154 5938.3338 19.1815 0 19.1815 0.0793 19.1022 19.1022
Haemagglutinin 25.1654 25.1654 0.5033 24.6621 0 24.6621 0.102 24.5602 24.5602
HCl 0 0 0 0 0 0 0 0 0
Inulin 0 0 0 0 0 0 0 0 0
Isopropanol 0 0 0 0 0 0 0 0 0
KCl 0 0 0 0 0 0 0 0 0
KH2PO4 0 0 0 0 0 0 0 0 0
L-Glutamine 987.3145 987.3145 984.1356 3.1789 0 3.1789 0.0131 3.1657 3.1657
Lactate 4.2992 4.2992 4.2853 0.0138 0 0.0138 0.0001 0.0138 0.0138
Media 23096.4782 23096.4782 23022.114 74.3642 0 74.3642 0.3074 74.0567 74.0567
Na2HPO4 0 0 0 0 275.8177 275.8177 1.1403 274.6774 274.6774
NaH2PO4 0 0 0 0 68.0664 68.0664 0.2814 67.7849 67.7849
NaHCO3 348.029 348.029 346.9084 1.1206 0 1.1206 0.0046 1.1159 1.1159
Nitrogen 0 0 0 0 0 0 0 0 0
Oxygen 0 0 0 0 0 0 0 0 0
Sodium Chloride 0 0 0 0 5134.0719 5134.0719 21.2257 5112.8462 5112.8462
Sodium Hydroxide 0 0 0 0 0 0 0 0 0
Water 0 0 0 0 0 0 0 0 0
WFI 963395.8699 963395.8699 960294.0058 3101.8641 125276.454 128378.3181 530.7528 127847.5653 127847.5653
Time Ref: Batch WFI In 1 Flush In 1 To WM (3) To WM (4) S-121 S-119 Salt/Buffer Addition S-101 Regen Input
Type Raw Material Raw Material Raw Material Raw Material
Total Flow kg 130.8076 69.6293 69.6293 132.4612 131.7712 131.7712 3.7039 135.4751 3.9425
Temperature °C 25 25 25 25.53 25.53 25.53 25 25.52 25
Pressure bar 1.013 1.013 1.013 2.963 2.963 2.965 1.013 3.05 1.013
Liq/Sol Vol Flow L 131.504 70 70 131.5169 131.5221 131.5221 1.9276 133.4495 3.78
Total Enthalpy kJ 13654.2186 7268.1864 7268.1864 13969.1246 13955.6595 13955.6311 230.0945 14185.6016 396.1479
Total Contents g 130807.5596 69629.3028 69629.3028 132461.235 131771.213 131771.213 3703.9153 135475.1283 3942.54
Ammonium 0 0 0 0 0 0 0 0 0
Carb. Dioxide 0 0 0 0 0 0 0 0 0
Cell Biomass 0 0 0 0 0 0 0 0 0
Glucose 0 0 0 12.0749 7.0273 7.0273 0 7.0273 0
Haemagglutinin 0 0 0 0.4863 24.0738 24.0738 0 24.0738 0
HCl 0 0 0 0 0 0 0 0 0
Inulin 0 0 0 0 0 0 0 0 0
Isopropanol 0 0 0 0 0 0 0 0 0
KCl 0 0 0 0 0 0 0 0 0
KH2PO4 0 0 0 0 0 0 0 0 0
L-Glutamine 0 0 0 2.0011 1.1646 1.1646 0 1.1646 0
Lactate 0 0 0 0.0087 0.0051 0.0051 0 0.0051 0
Media 0 0 0 46.8128 27.2439 27.2439 0 27.2439 0
Na2HPO4 0 0 0 173.6293 101.0482 101.0482 186.4744 287.5225 0
NaH2PO4 0 0 0 42.8483 24.9367 24.9367 46.0182 70.9549 0
NaHCO3 0 0 0 0.7054 0.4105 0.4105 0 0.4105 0
Nitrogen 0 0 0 0 0 0 0 0 0
Oxygen 0 0 0 0 0 0 0 0 0
Sodium Chloride 0 0 0 3231.9352 1880.911 1880.911 3471.4227 5352.3337 210.3385
Sodium Hydroxide 0 0 0 0 0 0 0 0 143.9579
Water 0 0 0 0 0 0 0 0 0
WFI 130807.5596 69629.3028 69629.3028 128950.7331 129704.3919 129704.3919 0 129704.3919 3588.2436
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Time Ref: Batch Wash Input AEB Elute EQ Input Regen Output Wash Output Elute Waste 1 EQ Output S-102 S-108
Type Raw Material Raw Material Raw Material
Total Flow kg 0.8704 2.8953 2.7567 3.9425 0.8704 2.9196 2.7567 135.4508 135.4508
Temperature °C 25 25 25 25 25 25 25 25.52 25.52
Pressure bar 1.013 1.013 1.013 1.013 1.013 1.013 1.013 3.05 3.049
Liq/Sol Vol Flow L 0.7942 2.7 2.7 3.7913 0.8277 2.818 2.7453 133.4252 133.4252
Total Enthalpy kJ 87.9651 292.4638 285.0596 396.1479 87.9651 294.6997 285.0596 14183.3657 14183.2413
Total Contents g 870.4404 2895.2892 2756.7 3942.54 870.4404 2919.6374 2756.7 135450.7801 135450.7801
Ammonium 0 0 0 0 0 0 0 0 0
Carb. Dioxide 0 0 0 0 0 0 0 0 0
Cell Biomass 0 0 0 0 0 0 0 0 0
Glucose 0 0 0 0 0 0 0 7.0273 7.0273
Haemagglutinin 0 0 0 0 0 3.3703 0 20.7035 20.7035
HCl 2.8402 0 0 0 2.8402 0 0 0 0
Inulin 0 0 0 0 0 0 0 0 0
Isopropanol 0 0 0 0 0 0 0 0 0
KCl 0 0 0 0 0 0 0 0 0
KH2PO4 0 0 0 0 0 0 0 0 0
L-Glutamine 0 0 0 0 0 0 0 1.1646 1.1646
Lactate 0 0 0 0 0 0 0 0.0051 0.0051
Media 0 0 0 0 0 20.9778 0 6.2661 6.2661
Na2HPO4 0 5.845 0 0 0 5.845 0 287.5225 287.5225
NaH2PO4 0 1.4424 0 0 0 1.4424 0 70.9549 70.9549
NaHCO3 0 0 0 0 0 0 0 0.4105 0.4105
Nitrogen 0 0 0 0 0 0 0 0 0
Oxygen 0 0 0 0 0 0 0 0 0
Sodium Chloride 91.042 233.1432 0 210.3385 91.042 233.1432 0 5352.3337 5352.3337
Sodium Hydroxide 0 0 54.0313 143.9579 0 0 54.0313 0 0
Water 0 0 0 0 0 0 0 0 0
WFI 776.5582 2654.8586 2702.6687 3588.2436 776.5582 2654.8586 2702.6687 129704.3919 129704.3919
Time Ref: Batch WFI In 2 Flush In 2 To WM (5) To WM (6) S-103 Dilution Water Buffer Addition S-104 EQ In.
Type Raw Material Raw Material Raw Material Raw Material Raw Material
Total Flow kg 132.7186 69.6293 69.6293 201.3068 66.8626 46.1586 0.2417 113.263 9.4463
Temperature °C 25 25 25 25.74 25.74 25 25 25.44 25
Pressure bar 1.013 1.013 1.013 3.049 3.049 1.013 1.013 2.34 1.013
Liq/Sol Vol Flow L 133.4252 70 70 200.1715 66.7261 46.4044 0.1381 113.2694 9.4455
Total Enthalpy kJ 13853.7013 7268.1864 7268.1864 21434.3107 7138.8854 4818.2233 3.3195 11960.3247 980.5212
Total Contents g 132718.6056 69629.3028 69629.3028 201306.7597 66862.626 46158.63 241.738 113262.994 9446.3261
Ammonium 0 0 0 0 0 0 0 0 0
Carb. Dioxide 0 0 0 0 0 0 0 0 0
Cell Biomass 0 0 0 0 0 0 0 0 0
Glucose 0 0 0 5.7349 1.2924 0 0 1.2924 0
Haemagglutinin 0 0 0 1.0254 19.6781 0 0 19.6781 0
HCl 0 0 0 0 0 0 0 0 0
Inulin 0 0 0 0 0 0 0 0 0
Isopropanol 0 0 0 0 0 0 0 0 0
KCl 0 0 0 0 0 0 0 0 0
KH2PO4 0 0 0 0 0 0 0 0 0
L-Glutamine 0 0 0 0.9504 0.2142 0 0 0.2142 0
Lactate 0 0 0 0.0041 0.0009 0 0 0.0009 0
Media 0 0 0 5.1137 1.1524 0 0 1.1524 0
Na2HPO4 0 0 0 234.643 52.8795 0 193.8898 246.7694 20.5628
NaH2PO4 0 0 0 57.9052 13.0496 0 47.8482 60.8978 5.0745
NaHCO3 0 0 0 0.335 0.0755 0 0 0.0755 0
Nitrogen 0 0 0 0 0 0 0 0 0
Oxygen 0 0 0 0 0 0 0 0 0
Sodium Chloride 0 0 0 4367.9623 984.3714 0 0 984.3714 82.0129
Sodium Hydroxide 0 0 0 0 0 0 0 0 0
Water 0 0 0 0 0 0 0 0 0
WFI 132718.6056 69629.3028 69629.3028 196633.0856 65789.9118 46158.63 0 111948.5418 9338.6759
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Time Ref: Batch Wash In. Elute. In Clean In Load Out Clean Out EQ/Wash Out Elute Waste 2 S-105 S-106
Type Raw Material Raw Material Raw Material
Total Flow kg 9.4463 9.602 8.7933 113.2441 8.7933 9.4463 9.4463 9.6209 9.6209
Temperature °C 25 25 25 25.44 25 25 25 25 25
Pressure bar 1.013 1.013 1.013 1.013 1.013 1.013 1.013 1.013 1.25
Liq/Sol Vol Flow L 9.4455 9.4455 9.4455 113.2514 9.4455 9.4455 9.4455 9.4635 9.4635
Total Enthalpy kJ 980.5212 984.2975 803.5453 11960.3206 803.5461 980.5221 980.5221 984.3015 984.3015
Total Contents g 9446.3261 9602.03 8793.2592 113244.103 8793.2679 9446.3356 9446.3356 9620.921 9620.921
Ammonium 0 0 0 0 0 0 0 0 0
Carb. Dioxide 0 0 0 0 0 0 0 0 0
Cell Biomass 0 0 0 0 0 0 0 0 0
Glucose 0 0 0 1.2924 0 0 0 0 0
Haemagglutinin 0 0 0 0.7871 0 0 0 18.891 18.891
HCl 0 0 0 0 0 0 0 0 0
Inulin 0 0 0 0 0 0 0 0 0
Isopropanol 0 0 2636.9639 0 2636.9665 0 0 0 0
KCl 0 0 0 0 0 0 0 0 0
KH2PO4 0 0 0 0 0 0 0 0 0
L-Glutamine 0 0 0 0.2142 0 0 0 0 0
Lactate 0 0 0 0.0009 0 0 0 0 0
Media 0 0 0 1.1524 0 0 0 0 0
Na2HPO4 20.5628 20.1932 0 246.7694 0 20.5628 20.5628 20.1932 20.1932
NaH2PO4 5.0745 4.9833 0 60.8978 0 5.0745 5.0745 4.9833 4.9833
NaHCO3 0 0 0 0.0755 0 0 0 0 0
Nitrogen 0 0 0 0 0 0 0 0 0
Oxygen 0 0 0 0 0 0 0 0 0
Sodium Chloride 82.0129 402.8244 0 984.3714 0 82.013 82.013 402.8244 402.8244
Sodium Hydroxide 0 0 237.4617 0 237.462 0 0 0 0
Water 0 0 0 0 0 0 0 0 0
WFI 9338.6759 9174.0291 5918.8335 111948.5418 5918.8395 9338.6852 9338.6852 9174.0291 9174.0291
Time Ref: Batch WFI In 3 Flush In 3 To WM (7) To WM (8) S-109 S-107 To WM (9) S-110 To WM (10) S-111 WFI for Dilution
Type Raw Material Raw Material Raw Material
Total Flow kg 9.4134 49.7352 49.7352 9.544 9.4903 9.4903 0.0011 9.4893 0.0018 9.4875 29.8411
Temperature °C 25 25 25 25.32 25.32 25.32 25.32 25.32 25.32 25.32 25
Pressure bar 1.013 1.013 1.013 1.25 1.25 1.251 1.013 1.251 1.013 1.251 1.013
Liq/Sol Vol Flow L 9.4635 50 50 9.4646 9.4646 9.4646 0.0011 9.4635 0.0017 9.4618 30
Total Enthalpy kJ 982.6071 5191.5617 5191.5617 997.4551 994.6896 994.6705 0.0558 994.6147 0.0902 994.5244 3114.937
Total Contents g 9413.3866 49735.2162 49735.2162 9543.9642 9490.3434 9490.3434 1.086 9489.2575 1.7556 9487.5018 29841.1298
Ammonium 0 0 0 0 0 0 0 0 0 0 0
Carb. Dioxide 0 0 0 0 0 0 0 0 0 0 0
Cell Biomass 0 0 0 0 0 0 0 0 0 0 0
Glucose 0 0 0 0 0 0 0 0 0 0 0
Haemagglutinin 0 0 0 0.3741 18.517 18.517 0.5555 17.9614 0.8981 17.0634 0
HCl 0 0 0 0 0 0 0 0 0 0 0
Inulin 0 0 0 0 0 0 0 0 0 0 0
Isopropanol 0 0 0 0 0 0 0 0 0 0 0
KCl 0 0 0 0 0 0 0 0 0 0 0
KH2PO4 0 0 0 0 0 0 0 0 0 0 0
L-Glutamine 0 0 0 0 0 0 0 0 0 0 0
Lactate 0 0 0 0 0 0 0 0 0 0 0
Media 0 0 0 0 0 0 0 0 0 0 0
Na2HPO4 0 0 0 12.7646 7.4287 7.4287 0.0004 7.4283 0.0007 7.4276 0
NaH2PO4 0 0 0 3.15 1.8332 1.8332 0.0001 1.8331 0.0002 1.833 0
NaHCO3 0 0 0 0 0 0 0 0 0 0 0
Nitrogen 0 0 0 0 0 0 0 0 0 0 0
Oxygen 0 0 0 0 0 0 0 0 0 0 0
Sodium Chloride 0 0 0 254.6336 148.1908 148.1908 0.0083 148.1825 0.0134 148.1691 0
Sodium Hydroxide 0 0 0 0 0 0 0 0 0 0 0
Water 0 0 0 0 0 0 0 0 0 0 0
WFI 9413.3866 49735.2162 49735.2162 9273.042 9314.3737 9314.3737 0.5216 9313.8521 0.8433 9313.0088 29841.1298
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Time Ref: Batch Final Buffer Inulin S-112 Water Removed Final Prod. Pump Energy In Energy Loss to Surr. Energy In from Steam
Type Raw Material Raw Material
Total Flow kg 0.0168 8.5 47.8454 39.1454 8.7
Temperature °C 25 25 25.07 20 20
Pressure bar 1.013 1.013 15.421 15.421 15.421
Liq/Sol Vol Flow L 0.0096 7.2423 46.714 39.2819 7.3363
Total Enthalpy kJ 0.2309 422.0936 4531.7819 3268.9265 346.4386 33210 6387998 6416758
Total Contents g 16.813 8500 47845.4446 39145.4385 8700.006
Ammonium 0 0 0 0 0
Carb. Dioxide 0 0 0 0 0
Cell Biomass 0 0 0 0 0
Glucose 0 0 0 0 0
Haemagglutinin 0 0 17.0634 0 17.0634
HCl 0 0 0 0 0
Inulin 0 8500 8500 0 8500
Isopropanol 0 0 0 0 0
KCl 0 0 0 0 0
KH2PO4 0 0 0 0 0
L-Glutamine 0 0 0 0 0
Lactate 0 0 0 0 0
Media 0 0 0 0 0
Na2HPO4 13.4851 0 20.9127 0 20.9127
NaH2PO4 3.3279 0 5.1608 0 5.1608
NaHCO3 0 0 0 0 0
Nitrogen 0 0 0 0 0
Oxygen 0 0 0 0 0
Sodium Chloride 0 0 148.1691 0 148.1691
Sodium Hydroxide 0 0 0 0 0
Water 0 0 0 0 0
WFI 0 0 39154.1386 39145.4385 8.7
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Appendix B: Economic Calculations 
 
B-1: Amortization Calculations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7,261,108.32$    
Qrtr. Per. 4 Rate 12%
3% Effective Rt. 314,132.81$        /3 months
1,256,531.25$    /year
46,953,496.74$  
Qrtr. Per. 4 Rate 12%
3% Effective Rt. 1,450,389.64$    /3 months
5,801,558.58$    /year
Disposable Technology
Equipment Amortization
Payment at t=0
Payment at t=0
Annual Total Payment
Annual Total Payment
Building Amortization
30,744,825.00$  
Qrtr. Per. 4 Rate 12%
3% Effective Rt. 1,330,094.24$    /3 months
5,320,376.95$    /year
58,691,870.93$  
Qrtr. Per. 4 Rate 12%
3% Effective Rt. 1,812,987.06$    /3 months
7,251,948.22$    /year
Conventional Technology
Equipment Amortization
Payment at t=0
Annual Total Payment
Payment at t=0
Annual Total Payment
Building Amortization
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B-2: Depreciation Calculations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year Dep. % Rate Depreciation Value (USD)
1 10.00% 14,552,755.47$                      
2 18.00% 26,194,959.84$                      
3 14.40% 20,955,967.87$                      
4 11.52% 16,764,774.30$                      
5 9.22% 13,417,640.54$                      
6 7.37% 10,725,380.78$                      
7 6.55% 9,532,054.83$                        
8 6.55% 9,532,054.83$                        
9 6.56% 9,546,607.59$                        
10 6.55% 9,532,054.83$                        
11 3.28% 4,773,303.79$                        
Disposable Technology
Year Dep. % Rate Conventional Value (USD)
1 10.00% 24,535,907.59$                       
2 18.00% 44,164,633.66$                       
3 14.40% 35,331,706.93$                       
4 11.52% 28,265,365.55$                       
5 9.22% 22,622,106.80$                       
6 7.37% 18,082,963.89$                       
7 6.55% 16,071,019.47$                       
8 6.55% 16,071,019.47$                       
9 0.0656 16,095,555.38$                       
10 0.0655 16,071,019.47$                       
11 0.0328 8,047,777.69$                         
Conventional Technology
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B-3: Revenue Based on Current Prices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concentration 15 μg/dose/strain
Product per Strain 330 g
Doses 22000000 doses/yr
Private Sale 11000000 doses/yr
Price Private Sale 7.65$                       $/dose
Public Sale 11000000 doses/yr
Price Public Sale 5.88$                       $/dose
Total Sales 148,830,000.00$  
Excise Tax for Private 8,250,000.00$      
Excise Tax for Public 8,250,000.00$      
Total Excise Tax 16,500,000.00$    
Revenue for Private 56,430,000.00$    
Revenue for Public 75,900,000.00$    
Total Revenue 132,330,000.00$  
Production
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B-4: Net Present Value of Disposable Based on Current Prices 
 
 
 
 
 
 
 
 
 
 
 
Year Fixed Capital Investment (USD) Working Capital (USD) Depreciation (USD) Sales (USD) Production Costs wo/Dep. (USD) Net Earnings (USD)
-2 (72,763,777.33)$                                -$                                   -$                             -$                         -$                                                         -$                             
-1 (72,763,777.33)$                                (3,478,616.09)$               -$                             -$                         -$                                                         -$                             
0 -$                                                       -$                                   14,552,755.47$        66,165,000.00$    (33,879,802.28)$                                   11,526,087.47$        
1 -$                                                       -$                                   26,194,959.84$        132,330,000.00$  (35,925,018.77)$                                   45,636,513.90$        
2 -$                                                       -$                                   20,955,967.87$        132,330,000.00$  (35,925,018.77)$                                   49,041,858.68$        
3 -$                                                       -$                                   16,764,774.30$        132,330,000.00$  (35,925,018.77)$                                   51,766,134.50$        
4 -$                                                       -$                                   13,417,640.54$        132,330,000.00$  (35,925,018.77)$                                   53,941,771.45$        
5 -$                                                       -$                                   10,725,380.78$        132,330,000.00$  (35,925,018.77)$                                   55,691,740.29$        
6 -$                                                       -$                                   9,532,054.83$          132,330,000.00$  (35,925,018.77)$                                   56,467,402.16$        
7 -$                                                       -$                                   9,532,054.83$          132,330,000.00$  (35,925,018.77)$                                   56,467,402.16$        
8 -$                                                       -$                                   9,546,607.59$          132,330,000.00$  (35,925,018.77)$                                   56,457,942.87$        
9 -$                                                       -$                                   9,532,054.83$          132,330,000.00$  (35,925,018.77)$                                   56,467,402.16$        
10 -$                                                       -$                                   4,773,303.79$          132,330,000.00$  (35,925,018.77)$                                   59,560,590.33$        
11 -$                                                       -$                                   -$                             132,330,000.00$  (35,925,018.77)$                                   62,663,237.80$        
12 -$                                                       -$                                   -$                             132,330,000.00$  (35,925,018.77)$                                   62,663,237.80$        
13 -$                                                       -$                                   -$                             132,330,000.00$  (35,925,018.77)$                                   62,663,237.80$        
14 -$                                                       -$                                   -$                             132,330,000.00$  (35,925,018.77)$                                   62,663,237.80$        
15 -$                                                       -$                                   -$                             132,330,000.00$  (35,925,018.77)$                                   62,663,237.80$        
16 -$                                                       -$                                   -$                             132,330,000.00$  (35,925,018.77)$                                   62,663,237.80$        
17 -$                                                       -$                                   -$                             132,330,000.00$  (35,925,018.77)$                                   62,663,237.80$        
18 -$                                                       -$                                   -$                             132,330,000.00$  (35,925,018.77)$                                   62,663,237.80$        
19 -$                                                       -$                                   -$                             132,330,000.00$  (35,925,018.77)$                                   62,663,237.80$        
20 -$                                                       3,478,616.09$                 -$                             132,330,000.00$  (35,925,018.77)$                                   62,663,237.80$        
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Year Discounted Cash Flow (USD) Present Value (USD) Cumulative Present Value (USD)
-2 (72,763,777.33)$                          (72,763,777.33)$         (72,763,777.33)$                                   
-1 (76,242,393.42)$                          (68,073,565.55)$         (140,837,342.88)$                                 
0 26,078,842.93$                            20,789,893.92$           (120,047,448.96)$                                 
1 71,831,473.74$                            51,128,224.18$           (68,919,224.78)$                                   
2 69,997,826.55$                            44,484,884.22$           (24,434,340.56)$                                   
3 68,530,908.80$                            38,886,278.10$           14,451,937.54$                                     
4 67,359,411.99$                            34,126,374.42$           48,578,311.96$                                     
5 66,417,121.07$                            30,043,732.60$           78,622,044.56$                                     
6 65,999,456.99$                            26,656,073.73$           105,278,118.29$                                  
7 65,999,456.99$                            23,800,065.83$           129,078,184.12$                                  
8 66,004,550.45$                            21,251,698.74$           150,329,882.86$                                  
9 65,999,456.99$                            18,973,266.77$           169,303,149.63$                                  
10 67,812,510.22$                            17,405,782.36$           186,708,931.99$                                  
11 62,663,237.80$                            14,360,796.77$           201,069,728.76$                                  
12 62,663,237.80$                            12,822,139.98$           213,891,868.74$                                  
13 62,663,237.80$                            11,448,339.26$           225,340,208.00$                                  
14 62,663,237.80$                            10,221,731.49$           235,561,939.49$                                  
15 62,663,237.80$                            9,126,545.97$             244,688,485.46$                                  
16 62,663,237.80$                            8,148,701.76$             252,837,187.22$                                  
17 62,663,237.80$                            7,275,626.57$             260,112,813.79$                                  
18 62,663,237.80$                            6,496,095.15$             266,608,908.94$                                  
19 62,663,237.80$                            5,800,084.96$             272,408,993.90$                                  
20 66,141,853.89$                            5,466,128.85$             277,875,122.75$                                  
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B-5: Net Present Value of Conventional based on Current Prices 
 
 
 
 
 
 
 
 
 
Year Fixed Capital Investment (USD) Working Capital (USD) Depreciation (USD) Sales (USD) Production Costs wo/Dep. (USD) Net Earnings (USD)
-4 (61,339,768.98)$                                -$                                    -$                              -$                             -$                                                        -$                             
-3 (61,339,768.98)$                                -$                                    -$                              -$                             -$                                                        -$                             
-2 (61,339,768.98)$                                -$                                    -$                              -$                             -$                                                        -$                             
-1 (61,339,768.98)$                                (36,803,861.39)$             -$                              -$                             -$                                                        -$                             
0 -$                                                       -$                                    24,535,907.59$         66,165,000.00$        (41,936,418.40)$                                 (199,761.89)$            
1 -$                                                       -$                                    44,164,633.66$         132,330,000.00$      (42,530,754.81)$                                 29,662,497.49$        
2 -$                                                       -$                                    35,331,706.93$         132,330,000.00$      (42,530,754.81)$                                 35,403,899.87$        
3 -$                                                       -$                                    28,265,365.55$         132,330,000.00$      (42,530,754.81)$                                 39,997,021.77$        
4 -$                                                       -$                                    22,622,106.80$         132,330,000.00$      (42,530,754.81)$                                 43,665,139.95$        
5 -$                                                       -$                                    18,082,963.89$         132,330,000.00$      (42,530,754.81)$                                 46,615,582.84$        
6 -$                                                       -$                                    16,071,019.47$         132,330,000.00$      (42,530,754.81)$                                 47,923,346.71$        
7 -$                                                       -$                                    16,071,019.47$         132,330,000.00$      (42,530,754.81)$                                 47,923,346.71$        
8 -$                                                       -$                                    9,546,607.59$           132,330,000.00$      (42,530,754.81)$                                 52,164,214.44$        
9 -$                                                       -$                                    9,532,054.83$           132,330,000.00$      (42,530,754.81)$                                 52,173,673.73$        
10 -$                                                       -$                                    4,773,303.79$           132,330,000.00$      (42,530,754.81)$                                 55,266,861.91$        
11 -$                                                       -$                                    -$                              132,330,000.00$      (42,530,754.81)$                                 58,369,509.37$        
12 -$                                                       -$                                    -$                              132,330,000.00$      (42,530,754.81)$                                 58,369,509.37$        
13 -$                                                       -$                                    -$                              132,330,000.00$      (42,530,754.81)$                                 58,369,509.37$        
14 -$                                                       -$                                    -$                              132,330,000.00$      (42,530,754.81)$                                 58,369,509.37$        
15 -$                                                       -$                                    -$                              132,330,000.00$      (42,530,754.81)$                                 58,369,509.37$        
16 -$                                                       -$                                    -$                              132,330,000.00$      (42,530,754.81)$                                 58,369,509.37$        
17 -$                                                       -$                                    -$                              132,330,000.00$      (42,530,754.81)$                                 58,369,509.37$        
18 -$                                                       -$                                    -$                              132,330,000.00$      (42,530,754.81)$                                 58,369,509.37$        
19 -$                                                       -$                                    -$                              132,330,000.00$      (42,530,754.81)$                                 58,369,509.37$        
20 -$                                                       36,803,861.39$               -$                              132,330,000.00$      (42,530,754.81)$                                 58,369,509.37$        
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Year Discounted Cash Flow (USD) Present Value (USD) Cumulative Present Value (USD)
-4 (61,339,768.98)$                          (61,339,768.98)$         (61,339,768.98)$                                   
-3 (61,339,768.98)$                          (54,767,650.87)$         (116,107,419.85)$                                 
-2 (61,339,768.98)$                          (48,899,688.28)$         (165,007,108.13)$                                 
-1 (98,143,630.37)$                          (69,856,697.54)$         (234,863,805.67)$                                 
0 24,336,145.70$                            15,466,060.55$           (219,397,745.12)$                                 
1 73,827,131.15$                            41,891,496.90$           (177,506,248.23)$                                 
2 70,735,606.80$                            35,836,859.78$           (141,669,388.45)$                                 
3 68,262,387.31$                            30,878,437.34$           (110,790,951.11)$                                 
4 66,287,246.75$                            26,772,307.19$           (84,018,643.92)$                                   
5 64,698,546.73$                            23,330,944.55$           (60,687,699.36)$                                   
6 63,994,366.19$                            20,604,473.20$           (40,083,226.16)$                                   
7 63,994,366.19$                            18,396,851.08$           (21,686,375.08)$                                   
8 61,710,822.03$                            15,839,630.98$           (5,846,744.10)$                                     
9 61,705,728.56$                            14,141,360.37$           8,294,616.27$                                       
10 60,040,165.70$                            12,285,407.45$           20,580,023.72$                                     
11 58,369,509.37$                            10,663,891.13$           31,243,914.86$                                     
12 58,369,509.37$                            9,521,331.37$             40,765,246.23$                                     
13 58,369,509.37$                            8,501,188.72$             49,266,434.95$                                     
14 58,369,509.37$                            7,590,347.07$             56,856,782.02$                                     
15 58,369,509.37$                            6,777,095.60$             63,633,877.62$                                     
16 58,369,509.37$                            6,050,978.22$             69,684,855.84$                                     
17 58,369,509.37$                            5,402,659.12$             75,087,514.96$                                     
18 58,369,509.37$                            4,823,802.79$             79,911,317.75$                                     
19 58,369,509.37$                            4,306,966.77$             84,218,284.52$                                     
20 95,173,370.76$                            6,270,221.85$             90,488,506.37$                                     
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B-6: IRR at 25% for Disposable Technology 
 
Some calculations were based on the sales prices and the conventional technology prices.  Thus, 
manufacturing costs for both technologies had to be recalculated for this step. 
 
 
 
 
 
 
 
 
 
Item Factor Costs
Total Materials Cost 16 3,356,252.71$                 
Labor Costs 1 489,453.52$                     
Utilities 0.5 244,726.76$                     
Depreciation (Estimate not used) 0.6 398,555.01$                     
Other (Royalties, Licensure, etc) 1 1,643,165.39$                 
Equipment Amortization 12% Int. over 10 years 1,256,531.25$                 
Building Amortization 12% Int. over 30 years 5,801,558.58$                 
Land Tax and Insurance 4% of Fixed Capital 5,821,102.19$                 
Plant Overhead 25% of Labor Costs 122,363.38$                     
Manufacturing Costs 18,735,153.77$               
General Expenses 11.55% of Sales 13,750,516.75$               
Total Product Cost 32,485,670.53$               
Total Product Cost 1st Year 30,440,454.03$               
Disposable Technology
Item Factor Cost
Total Materials Cost 0.06 209,765.79$                
Labor Costs 0.14 489,453.52$                
Utilities 0.14 489,453.52$                
Depreciation (Estimate not used) 0.19 664,258.35$                
Other (Royalties, Licensure, etc) 0.47 1,643,165.39$             
Equipment Amortization 12% Int. over 10 years 5,320,376.95$             
Building Amortization 12% Int. over 30 years 7,251,948.22$             
Land Tax and Insurance 4% of Fixed Capital 9,814,363.04$             
Plant Overhead 25% of Labor Costs 122,363.38$                
Manufacturing 25,340,889.81$          
General Expenses 11.55% of Sales 13,750,516.75$          
Total Product Cost 39,091,406.57$          
Total Product Cost 1st Year 38,497,070.15$          
Conventional Technology
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Concentration 15 μg/dose/strain
Product per Strain 330 g
Doses 22000000 doses/yr
Private Sale 11000000 doses/yr
Price Private Sale 7.04$                            $/dose
Public Sale 11000000 doses/yr
Price Public Sale 3.78$                            $/dose
Revenue for Private 69,206,046.55$         
Revenue for Public 33,346,046.55$         
Excise Tax for Private 8,250,000.00$           
Excise Tax for Public 8,250,000.00$           
Total Excise Tax 16,500,000.00$         
Total Revenue 102,552,093.10$      
Total Sales 119,052,093.10$      
Production
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Year Fixed Capital Investment (USD) Working Capital (USD) Depreciation (USD) Sales (USD) Production Costs wo/Dep. (USD)
-2 (72,763,777.33)$                               -$                                    -$                              -$                            -$                                                           
-1 (72,763,777.33)$                               (3,478,616.09)$                -$                              -$                            -$                                                           
0 -$                                                      -$                                    14,552,755.47$         51,276,046.55$       (33,879,802.28)$                                    
1 -$                                                      -$                                    26,194,959.84$         102,552,093.10$     (35,925,018.77)$                                    
2 -$                                                      -$                                    20,955,967.87$         102,552,093.10$     (35,925,018.77)$                                    
3 -$                                                      -$                                    16,764,774.30$         102,552,093.10$     (35,925,018.77)$                                    
4 -$                                                      -$                                    13,417,640.54$         102,552,093.10$     (35,925,018.77)$                                    
5 -$                                                      -$                                    10,725,380.78$         102,552,093.10$     (35,925,018.77)$                                    
6 -$                                                      -$                                    9,532,054.83$           102,552,093.10$     (35,925,018.77)$                                    
7 -$                                                      -$                                    9,532,054.83$           102,552,093.10$     (35,925,018.77)$                                    
8 -$                                                      -$                                    9,546,607.59$           102,552,093.10$     (35,925,018.77)$                                    
9 -$                                                      -$                                    9,532,054.83$           102,552,093.10$     (35,925,018.77)$                                    
10 -$                                                      -$                                    4,773,303.79$           102,552,093.10$     (35,925,018.77)$                                    
11 -$                                                      -$                                    -$                              102,552,093.10$     (35,925,018.77)$                                    
12 -$                                                      -$                                    -$                              102,552,093.10$     (35,925,018.77)$                                    
13 -$                                                      -$                                    -$                              102,552,093.10$     (35,925,018.77)$                                    
14 -$                                                      -$                                    -$                              102,552,093.10$     (35,925,018.77)$                                    
15 -$                                                      -$                                    -$                              102,552,093.10$     (35,925,018.77)$                                    
16 -$                                                      -$                                    -$                              102,552,093.10$     (35,925,018.77)$                                    
17 -$                                                      -$                                    -$                              102,552,093.10$     (35,925,018.77)$                                    
18 -$                                                      -$                                    -$                              102,552,093.10$     (35,925,018.77)$                                    
19 -$                                                      -$                                    -$                              102,552,093.10$     (35,925,018.77)$                                    
20 -$                                                      3,478,616.09$                 -$                              102,552,093.10$     (35,925,018.77)$                                    
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Net Earnings (USD) Discounted Cash Flow (USD) Present Value (USD) Cumulative Present Value (USD)
-$                               (72,763,777.33)$                          (72,763,777.33)$         (72,763,777.33)$                                   
-$                               (76,242,393.42)$                          (60,993,914.74)$         (133,757,692.06)$                                 
1,848,267.72$             16,401,023.19$                            10,496,654.84$           (123,261,037.22)$                                 
26,280,874.41$          52,475,834.25$                            26,867,627.14$           (96,393,410.09)$                                   
29,686,219.19$          50,642,187.06$                            20,743,039.82$           (75,650,370.26)$                                   
32,410,495.02$          49,175,269.31$                            16,113,752.25$           (59,536,618.02)$                                   
34,586,131.96$          48,003,772.50$                            12,583,900.94$           (46,952,717.08)$                                   
36,336,100.80$          47,061,481.58$                            9,869,508.02$             (37,083,209.06)$                                   
37,111,762.67$          46,643,817.50$                            7,825,534.01$             (29,257,675.04)$                                   
37,111,762.67$          46,643,817.50$                            6,260,427.21$             (22,997,247.83)$                                   
37,102,303.38$          46,648,910.96$                            5,008,888.67$             (17,988,359.16)$                                   
37,111,762.67$          46,643,817.50$                            4,006,673.41$             (13,981,685.74)$                                   
40,204,950.84$          48,456,870.73$                            3,329,930.80$             (10,651,754.94)$                                   
43,307,598.31$          43,307,598.31$                            2,380,860.40$             (8,270,894.55)$                                     
43,307,598.31$          43,307,598.31$                            1,904,688.32$             (6,366,206.23)$                                     
43,307,598.31$          43,307,598.31$                            1,523,750.65$             (4,842,455.58)$                                     
43,307,598.31$          43,307,598.31$                            1,219,000.52$             (3,623,455.05)$                                     
43,307,598.31$          43,307,598.31$                            975,200.42$                 (2,648,254.64)$                                     
43,307,598.31$          43,307,598.31$                            780,160.33$                 (1,868,094.30)$                                     
43,307,598.31$          43,307,598.31$                            624,128.27$                 (1,243,966.03)$                                     
43,307,598.31$          43,307,598.31$                            499,302.61$                 (744,663.42)$                                         
43,307,598.31$          43,307,598.31$                            399,442.09$                 (345,221.33)$                                         
43,307,598.31$          46,786,214.40$                            345,221.33$                 0.00$                                                        
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B-7: IRR at 25% for Conventional Technology 
 
Some calculations were based on the sales price.  Thus, manufacturing costs for conventional 
technology had to be recalculated for this step. 
 
 
 
 
 
 
 
 
 
Item Factor Cost
Total Materials Cost 0.06 209,765.79$              
Labor Costs 0.14 489,453.52$              
Utilities 0.14 489,453.52$              
Depreciation (Estimate not used) 0.19 664,258.35$              
Other (Royalties, Licensure, etc) 0.47 1,643,165.39$          
Equipment Amortization 12% Int. over 10 years 5,320,376.95$          
Building Amortization 12% Int. over 30 years 7,251,948.22$          
Land Tax and Insurance 4% of Fixed Capital 9,814,363.04$          
Plant Overhead 25% of Labor Costs 122,363.38$              
Manufacturing 25,340,889.81$        
General Expenses 11.55% of Sales 25,090,531.29$        
Total Product Cost 50,431,421.10$        
Total Product Cost 1st Year 49,837,084.69$        
Conventional Technology
Concentration 15 μg/dose/strain
Product per Strain 330 g
Doses 22000000 doses/yr
Private Sale 11000000 doses/yr
Price Private Sale 11.50$                                   $/dose
Public Sale 11000000 doses/yr
Price Public Sale 8.24$                                      $/dose
Revenue for Private 118,297,018.57$                
Revenue for Public 82,437,018.57$                   
Excise Tax for Private 8,250,000.00$                     
Excise Tax for Public 8,250,000.00$                     
Total Excise Tax 16,500,000.00$                   
Total Revenue 200,734,037.15$                
Total Sales 217,234,037.15$                
Production
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Year Fixed Capital Investment (USD) Working Capital (USD) Depreciation (USD) Sales (USD) Production Costs wo/Dep. (USD)
-4 (61,339,768.98)$                                -$                                    -$                            -$                                        -$                                                          
-3 (61,339,768.98)$                                -$                                    -$                            -$                                        -$                                                          
-2 (61,339,768.98)$                                -$                                    -$                            -$                                        -$                                                          
-1 (61,339,768.98)$                                (36,803,861.39)$             -$                            -$                                        -$                                                          
0 -$                                                       -$                                    24,535,907.59$       100,367,018.57$                (41,936,418.40)$                                   
1 -$                                                       -$                                    44,164,633.66$       200,734,037.15$                (42,530,754.81)$                                   
2 -$                                                       -$                                    35,331,706.93$       200,734,037.15$                (42,530,754.81)$                                   
3 -$                                                       -$                                    28,265,365.55$       200,734,037.15$                (42,530,754.81)$                                   
4 -$                                                       -$                                    22,622,106.80$       200,734,037.15$                (42,530,754.81)$                                   
5 -$                                                       -$                                    18,082,963.89$       200,734,037.15$                (42,530,754.81)$                                   
6 -$                                                       -$                                    16,071,019.47$       200,734,037.15$                (42,530,754.81)$                                   
7 -$                                                       -$                                    16,071,019.47$       200,734,037.15$                (42,530,754.81)$                                   
8 -$                                                       -$                                    9,546,607.59$          200,734,037.15$                (42,530,754.81)$                                   
9 -$                                                       -$                                    9,532,054.83$          200,734,037.15$                (42,530,754.81)$                                   
10 -$                                                       -$                                    4,773,303.79$          200,734,037.15$                (42,530,754.81)$                                   
11 -$                                                       -$                                    -$                            200,734,037.15$                (42,530,754.81)$                                   
12 -$                                                       -$                                    -$                            200,734,037.15$                (42,530,754.81)$                                   
13 -$                                                       -$                                    -$                            200,734,037.15$                (42,530,754.81)$                                   
14 -$                                                       -$                                    -$                            200,734,037.15$                (42,530,754.81)$                                   
15 -$                                                       -$                                    -$                            200,734,037.15$                (42,530,754.81)$                                   
16 -$                                                       -$                                    -$                            200,734,037.15$                (42,530,754.81)$                                   
17 -$                                                       -$                                    -$                            200,734,037.15$                (42,530,754.81)$                                   
18 -$                                                       -$                                    -$                            200,734,037.15$                (42,530,754.81)$                                   
19 -$                                                       -$                                    -$                            200,734,037.15$                (42,530,754.81)$                                   
20 -$                                                       36,803,861.39$               -$                            200,734,037.15$                (42,530,754.81)$                                   
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Year Net Earnings (USD) Discounted Cash Flow (USD) Present Value (USD) Cumulative Present Value (USD)
-4 -$                             (61,339,768.98)$                          (61,339,768.98)$         (61,339,768.98)$                                   
-3 -$                             (61,339,768.98)$                          (49,071,815.18)$         (110,411,584.16)$                                 
-2 -$                             (61,339,768.98)$                          (39,257,452.15)$         (149,669,036.31)$                                 
-1 -$                             (98,143,630.37)$                          (50,249,538.75)$         (199,918,575.05)$                                 
0 22,031,550.18$        46,567,457.77$                            19,074,030.70$           (180,844,544.35)$                                 
1 74,125,121.64$        118,289,755.30$                         38,761,187.02$           (142,083,357.33)$                                 
2 79,866,524.01$        115,198,230.94$                         30,198,525.05$           (111,884,832.28)$                                 
3 84,459,645.91$        112,725,011.46$                         23,640,148.32$           (88,244,683.96)$                                   
4 88,127,764.10$        110,749,870.90$                         18,580,745.06$           (69,663,938.90)$                                   
5 91,078,206.99$        109,161,170.88$                         14,651,364.34$           (55,012,574.56)$                                   
6 92,385,970.86$        108,456,990.33$                         11,645,480.66$           (43,367,093.89)$                                   
7 92,385,970.86$        108,456,990.33$                         9,316,384.53$             (34,050,709.36)$                                   
8 96,626,838.59$        106,173,446.17$                         7,296,183.66$             (26,754,525.70)$                                   
9 96,636,297.88$        106,168,352.71$                         5,836,666.92$             (20,917,858.78)$                                   
10 99,729,486.05$        104,502,789.85$                         4,596,081.30$             (16,321,777.48)$                                   
11 102,832,133.52$      102,832,133.52$                         3,618,084.05$             (12,703,693.43)$                                   
12 102,832,133.52$      102,832,133.52$                         2,894,467.24$             (9,809,226.19)$                                     
13 102,832,133.52$      102,832,133.52$                         2,315,573.79$             (7,493,652.40)$                                     
14 102,832,133.52$      102,832,133.52$                         1,852,459.03$             (5,641,193.37)$                                     
15 102,832,133.52$      102,832,133.52$                         1,481,967.23$             (4,159,226.14)$                                     
16 102,832,133.52$      102,832,133.52$                         1,185,573.78$             (2,973,652.36)$                                     
17 102,832,133.52$      102,832,133.52$                         948,459.02$                 (2,025,193.34)$                                     
18 102,832,133.52$      102,832,133.52$                         758,767.22$                 (1,266,426.12)$                                     
19 102,832,133.52$      102,832,133.52$                         607,013.78$                 (659,412.34)$                                         
20 102,832,133.52$      139,635,994.90$                         659,412.34$                 (0.00)$                                                      
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Appendix C: Growth Kinetics and Reactor Design 
 
C-1: Growth Rate Data [9] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time (h) Cell Density (Cells/mL)
0.0 1.02E+05
16.5 1.06E+05
39.0 1.67E+05
62.5 3.05E+05
88.0 8.37E+05
112.0 1.99E+06
136.5 3.46E+06
159.5 4.32E+06
192.5 4.56E+06
208.0 4.47E+06
Kinetics Growth Data
Log Phase y = 45473 * exp          ( 0.0325 x)
Lag Phase y = 102000 * exp          ( 0.00023 x)
x is time (hr) y is cell density (cells/mL) Target Conc. 2.77E+06
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C-2: Seeding Calculations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Starting Vial Thaw End Lag Phase End Thaw 1st Pass End 1st Pass 2nd Pass End 2nd Pass
Concentration (cell/mL) 1.0E+07 5.00E+05 5.03E+05 2.77E+06 5.00E+05 2.77E+06 5.00E+05 2.77E+06
Volume (mL) 1.0 20.0 20.0 20.0 110.72 110.720 612.946 612.9
Time of Phase (hr) 0 0 25.0 52.5 0 52.7 0 52.7
Total Time (hr) 0 0 25.0 77.51 77.51 130.17 130.17 182.82
Cell Mass (g) 0.0020 0.0111 0.0613 0.3393
Glucose Consumed (g) 0.0012 0.0051 0.0282 0.1561
L-Glutamine Cons. (g) 0.0009 0.0038 0.0212 0.1172
CO2 produced (g) 0.0000 0.0000 0.0001 0.0004
O2 consumed (g) 0.0015 0.0060 0.0335 0.1853
Lactate (g) 0.0015 0.0063 0.0349 0.1932
Ammonium Ion (g) 0.0001 0.0003 0.0017 0.0000
Other Consumed (g) 0.0000 0.0007 0.0041 0.0225
Unity 0.0000 0.0020 0.0111 0.0518
% Error of Mass Balance -0.3% 6.0% 6.0% 5.1%
Seeding Calculations
Change in Vol. Scale 3rd Pass End 3rd Pass 4th Pass End 4th Pass 5th Pass End 5th Pass 6th Pass End 6th Pass Bio Reactor
Concentration (cell/mL) 5.00E+05 2.77E+06 5.00E+05 2.77E+06 5.00E+05 2.77E+06 5.00E+05 2.77E+06 8.16E+05
Volume (L) 3.39 3.39 18.23 18.232 50.5 50.5 279.575 279.6 949
Time of Phase (hr) 0 52.65 0 52.65 0 52.68 0 52.68 0
Total Time (hr) 182.82 235.48 235.48 288.13 288.13 340.81 340.81 393.483 393.483
Cell Mass (g) 1.88 10.09 27.96 154.8848 154.88
Glucose Consumed (g) 0.86 4.64 12.87 71.27 0.00
L-Glutamine Cons. (g) 0.65 3.49 9.66 53.51 0.00
CO2 produced (g) 0.00 0.01 0.03 0.18 0.00
O2 consumed (g) 1.03 5.51 15.27 84.62 0.00
Lactate (g) 1.07 5.75 15.92 88.21 0.00
Ammonium Ion (g) 0.05 0.29 0.79 4.40 0.00
Other Consumed (g) 0.12 0.67 1.85 10.26 0.00
Unity 0.340 1.827 5.056 28.011
% Error of Mass Balance 6.00% 6.00% 5.99% 5.99%
Seeding Calculations
Infection Line End Line
Volume Initial (L) 9.1
Volume Final (L) 50.0
Conc. (cells/L) 5.05E+05
Time (hr) 0 120
Time to Inoculation (hr) 6.64
68 
 
 
 
 
C-3: Production Bioreactor Calculations 
 
 
 
 
 
 
 
 
 
 
 
 
Total Produced/Consumed
Cell Mass (g) 154.885
Glucose Consumed (g) 83.406
L-Glutamine Cons. (g) 62.615
CO2 produced (g) 0.210
O2 consumed (g) 99.017
Lactate (g) 103.221
Ammonium Ion (g) 5.136
Other Consumed (g) 12.008
Unity 6.406
% Error of Mass Balance 1.23%
Change in Vol. Scale Bio Reactor Growth to Infection Harvest
Concentration (cell/mL) 8.16E+05 1.63E+06 2.77E+06
Volume (L) 949 949 999
Time of Phase (hr) 0.00 21.3 72
Total Time (hr) 393.5 414.8 486.77
Cell Mass (g) 154.9 309.4 554.01686
Glucose Consumed (g) 0.0 1716.5
L-Glutamine Cons. (g) 0.0 1288.6
CO2 produced (g) 0.000 4.3
O2 consumed (g) 0.0 2037.8
Lactate (g) 0.0 2124.3
Ammonium Ion (g) 0.00 105.9
Other Consumed (g) 0.00 247.1
Haemagglutinin (g) 25.20777
Cell Mass Remainder 528.809
Unity 50.044
% Error of Mass Balance 12.10%
Production Bioreactor
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C-4: Calculation of Runs per Year Based on Strain Type [17] 
 
 
 
It was noted that different strains have different production yields.  Thus, calculations were done 
to determine the effective overall yield of the process.  Then, feeding the conversion number 
back into the production reactor calculation, a new total yield was produced, and the downstream 
effective yield determined the overall hemagglutinin content per batch.  Based on 330g per 
strain, this was used to determine the number of batches each year. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Process 1 (In. A) Process 2 (In. A) Process 2 (In. B)
Conversion (mg/10^9 Cells) 9.1 11.4 15.5
HA Estimate (g/batch) 25.21 31.58 42.94
HA Start (g/batch) 25.17 31.53 42.86
Percent Difference (%) -0.168% -0.168% -0.168%
HA Finish (g/batch) 17.063 21.38 29.06
Effective Yeild (%) 67.80% 67.80% 67.80%
Total Batches (per strain) 19.34 15.44 11.35
Normallized 20 16 12
Total Runs/Year 48
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Appendix D: Other Information 
 
D-1: UV Reactor/Lamp Design [47] 
 
 
 
 
 
 
 
 
 
 
 
 
D-2: Data Table of Market Information 
 
 
 
 
 
6600 μWs/cm^2
0.02376 kWhr/cm^2
6.6 mJ/cm^2
To Kill Influenza
Flow 10 GPM
Flow 54510 LPD
Dose 30 mJ/cm^2
Trojan UVMax Max Pro
1000mJ/cm^2           = 1 kWhr/m^3
          = 0.001 kWhr/L
Energy Conversion
Season Doses Distributed (millions) Source
2000-01 70.4 [3]
2001-02 77.7 [3]
2002-03 83.5 [3]
2003-04 83.1 [3]
2004-05 57.0 [3]
2005-06 81.5 [3]
2006-07 102.5 [3]
2007-08 112.8 [3]
2008-09 143 [2]
2010-11 163.0 [1]
2011-12 132.1 [1]
2012-13 134.9 [1]
2013-14 134.5 [1]
Market Trends for Dose Distribution
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Appendix E: Explanation of Calculations 
 
E-1: Kinetic Growth Rates 
 
An equation was supplied in Baculovirus [9] that calculated the growth rate of cells as a function 
of time.  The equation is the following: 
 
𝑵 = 𝑵𝟎 ∗ 𝐞𝐱𝐩⁡(𝝁 ∗ 𝒕) 
 
Where t is time, N0 is the cell count at the start, N is the cell count at the end of the time, and µ is 
the specific growth rate 0.0325hr-1.  N0 was 5.00*10
5 cells/mL, and N was the target 
concentration of 2.77*106 cells/mL.  Time was found using an Excel “What-If” analysis for each 
reaction step.  Once the target concentration was found, the new volume was found with the 
following equation: 
 
𝑽 =
𝑵
𝑵𝟎
∗ 𝑽𝟎 
 
Where V is the working volume of the next reactor and V0 is the old working volume.  After the 
third passage calculation, the volume was converted from mL to L.  Using these equations, the 
time of each growth phase could be calculated based on the higher end of the logarithmic growth 
phase.  Ideally, the working volume was between 10% and 50% of the overall reactor volume, 
and passages were processed in the same reactor to reduce the total amount of reactors needed 
for each phase of the process. 
 
The exception is the production reactor, where the initial working volume is just above 5% of the 
total volume.  However, the working volume reaches 10% of the total volume within a few 
hours. 
 
E-2: Calculation of Consumption/Production Rates 
 
Numerous sources stated that there were many components consumed or produced during the 
process.  Baculovirus stated that while items such as CO2, ammonium, and lactate were 
produced, they were not produced at such a rate to inhibit growth of the insect cells [9].  These 
items, along with the consumption of the primary components L-glutamine, glucose, and oxygen, 
were calculated in their production/consumption rates using the following equation: 
 
𝒓𝑨 = 𝒌𝑨 ∗ 𝒄𝑨 
 
This is the simple rate law that was assumed.  However, in the given rates, k, for the above 
compounds, the production/consumption is dependent upon time and cellular concentration [15, 
16] using the units mass/cells/time.  Thus, the rate law is modified to the following: 
 
𝒓𝑨 = 𝒌𝑨 ∗ 𝑵 
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This derivation becomes useful in the calculation of the production/consumption of a given 
chemical.  It converts the rate into a function of time, t.  A problem is seen, though, in trying to 
determine the total amount produced/consumed in each process: 
 
𝒓𝑨 = 𝒌𝑨 ∗ 𝑵𝟎 ∗ 𝐞𝐱𝐩⁡(𝝁 ∗ 𝒕) 
 
In order to calculate the amount of mass produced, the term must be integrated from time 0 to the 
final time t.  By multiplying both sides by dt (essentially 1 or dt/dt on one side), and then 
integrating, a new equation is obtained: 
 
𝒄𝑨 = (𝒌𝑨 ∗
𝑵𝟎
𝝁
∗ 𝐞𝐱𝐩(𝝁 ∗ 𝒕) − 𝒌𝑨 ∗
𝑵𝟎
𝝁
) 
 
Merging the other side and multiplying by the final volume of each passage, the total mass is 
calculated.  This yields the following final equation: 
 
𝒎𝑨 = 𝒌𝑨 ∗
𝑵𝟎
𝝁
∗ (𝐞𝐱𝐩(𝝁 ∗ 𝒕) − 𝟏) ∗ 𝑽 
 
This is the generic final equation used to calculate the production or consumption of a given 
component.  There is an interesting note about the equation above: the given rate law does not 
have an inherent negative in the front, as is normal with rate laws.  The reason is that cells were 
produced during the reaction, and due to the cellular production rate, a cancelling negative would 
not have been yielded.  This meant that the rate constant had to be multiplied by the integer -1 or 
1, depending on if the component was consumed or produced.  If the component was produced, 
then it was multiplied by 1.  If the component was consumed, then the rate constant was 
multiplied by -1.  Thus, the positive or negative value reflected what side of the reaction the 
component fell on.  The kinetic constants are summarized in the following table: 
 
 
 
In the full reported table in Appendix C, the absolute value of all the products was taken, 
yielding positive values for all the masses.  In this case, the usage or production of an item was 
noted in the side.  All other components consumed were put into one main term and a single rate 
constant for their consumption was derived using Excel “Solver” and the overall mass balance 
being as close to 0 as possible.  The error of the overall mass balance being 1.23% was deemed 
acceptable for the calculations.  SuperPro v8.5 did not agree with the production/consumption of 
k for glucose cons (g/cell/hr) 3.65E-12
k for glutamine cons (g/cell/hr) 2.74E-12
k for carbon dioxide (g/cell/hr) 9.17E-15
k for oxygen (g/cell/hr) 4.33E-12
k for lactate (g/cell/hr) 4.52E-12
k for ammonium (g/cell/hr) 2.25E-13
k for other (g/cell/hr) 5.25E-13
Kinetic Constants
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the amount calculated.  This was not reconciled and could be due to the media consumption term 
in SuperPro being too high or too low. 
 
E-3: Infection Production 
 
The amount of hemagglutinin produced was based on a mass per cellular amount.  It was 
calculated using a simple equation: 
 
𝒎𝒗𝒊𝒓𝒖𝒔 = 𝒄𝒄𝒆𝒍𝒍𝒔 ∗
𝟏𝟎𝟎𝟎𝒎𝑳
𝟏𝑳
∗
𝑽
𝟏𝟎𝟗
𝟏𝟎𝟎𝟎𝒎𝒈
𝒈
∗ 𝟗. 𝟏 
 
Where 9.1 is the milligrams of hemagglutinin produced per 109 cells [17].  The various values 
found were used to find this value in each step.  The total yield was calculated based on the 
effective yield predicted by SuperPro and the literature.  This was performed for each strain, with 
9.1 being the lowest value. 
 
E-4: Simple Economic Calculations 
 
Factors used to calculate the value of the various components of disposable technology given 
were based on the value of conventional equipment [20].  Thus, using the value of the disposable 
equipment, the value of the conventional equipment was found to be the following: 
 
𝑬𝒄𝒐𝒏𝒗 =
𝑬𝒅𝒊𝒔𝒑
𝒇𝟏𝒇𝟏
′ ∗ 𝒄
 
 
Then, using this equation, the values of all the parts of the capital costs were calculated: 
 
𝑪𝒅𝒊𝒔𝒑 = 𝒄 ∗ 𝑬𝒄𝒐𝒏𝒗𝒇𝒊𝒇𝒊
′ 
 
This was a similar process applied using the running costs and other factors, and utilized the 
materials costs of the disposable process for the manufacturing costs. 
 
The following equations summarize the other major economic equations used. 
 
𝑵𝒆𝒕⁡𝑬𝒂𝒓𝒏.𝒋= (𝑹𝒆𝒗.𝒋− 𝑪𝒐𝒔𝒕𝒔𝒋 −𝑫𝒆𝒑.𝒋 ) ∗ (𝟏 − 𝟎. 𝟑𝟓) 
 
𝑫𝒊𝒔𝒄𝒐𝒖𝒏𝒕. 𝑪𝒂𝒔𝒉⁡𝑭𝒍𝒐𝒘𝒋 = 𝑵𝒆𝒕⁡𝑬𝒂𝒓𝒏.𝒋+𝑫𝒆𝒑.𝒋+ 𝑭𝑪𝑰𝒋 +𝑾𝑪𝒋 
 
𝑷𝒓𝒆𝒔𝒆𝒏𝒕⁡𝑽𝒂𝒍𝒖𝒆𝒋 = 𝑫𝑪𝑭𝒋 ∗ (𝟏 + 𝒓)
−𝒏+𝒋 
 
𝑵𝑷𝑽 =∑𝑷𝑽𝒋
𝒋
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In the present value equation, n is the year in which the first capital expenditure is made.  This 
results in the value of the initial investment being valued in dollars of that year, rather than 
presented at a higher value than what is invested at that time before the plant begins operation.  
This reduces the value of future earnings based on the present value calculation. 
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Appendix F: MSDS and SDS Analyses in Brief 
 
The following section is a brief analysis of the chemicals used in the process that have the 
potential to be problematic or are unique.  This is a supplementary section to the Safety, Health, 
and Environmental Considerations in section 9.0 of the report. 
 
EXCELL 420- 
It is a non-hazardous substance.  It has HMIS and NFPA ratings of 0 in every category, making it 
safe for use in the process.  It contains L-glutamine, and no other properties are reported in the 
MSDS [53]. 
 
Sodium Bicarbonate- 
It slightly hazardous if it comes into contact with skin, eyes, or is ingested.  It acts as an irritant.  
It is not flammable, carcinogenic, or teratogenic.  If heated too much, it will emit acrid and 
irritating smoke.  Use safety glasses, lab coat, and dust respirator when using.  No exposure 
limits available [54]. 
 
Hydrochloric Acid- 
Hydrochloric acid is primarily an irritant if ingested or if a person is exposed.  Severe over 
exposure to this chemical can result in death, if not properly treated.  Hydrochloric acid is 
reactive with certain chemicals, though, it is non-flammable.  Wear gloves, eye protection, and 
safety coats when working with it.  If spilled, it can be easily neutralized with a diluted solution 
of sodium carbonate.  If a large spill occurs, it can be contained with dry earth or sand, use water 
to prevent vapors, and containment is necessary.  The PEL is 5ppm or 7mg/m3.  It is highly 
reactive with metals and is extremely corrosive [55]. 
 
Isopropanol- 
It is a slight irritant if it comes into contact with skin.  It is toxic to the liver, kidneys, and central 
nervous system if exposed.  UFL 2%.  LFL 12.7%.  FP 11.667°C.  Isopropanol is highly 
flammable.  If it catches fire, either a dry chemical or foam should be used to contain the blaze.  
Goggles, lab coat, and vapor respirator should be worn at all times with gloves.  The 200 STEL 
is 400ppm [56]. 
 
Sodium Phosphate, Dibasic- 
Mild skin irritant if exposed.  It is not flammable.  If it is spilled, it can be moved or shoveled 
into the nearest waste disposal container.  It is only a slight irritant to skin or if ingested [57]. 
 
Sodium Phosphate, Monobasic- 
It is a slight irritant to the skin or if ingested/inhaled.  It is not classified as a hazardous material 
otherwise.  PPE includes splash goggles, dust respirator, gloves, boots, and a full suit [58]. 
 
Sodium Hydroxide- 
A caustic base that is corrosive to skin, eyes, and dangerous if inhaled or ingested.  Damage is 
based on length of contact, and thus, should be cleaned away/removed as soon as possible.  The 
substance is non-flammable, but is highly reactive with metal materials.  It can react with certain 
chemicals to form explosive components.  The TLV is 2mg/m3 and the PEL is 2mg/m3.  Those 
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working with it should wear vapor and dust respirators, goggles, boots, gloves, and a synthetic 
apron.  Do not wash away with water and prevent entry into sewers.  Contain if possible and 
dilute with acetic acid solution. 
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Appendix G: Gantt Charts from SuperPro 
 
G-1: Gantt Chart of the Upstream Process for 1 Section (SuperPro Designer v8.5) 
 
 
 
 
 
 
 
 
Total Occ.T ime
TFR-101
DCS-101
RBR-101
SDLB-102
RBS-101
SDLB-101
SDLB-104
DSBS-101
SDLB-103
RBS-102
DBS-101
Total Occ.T ime (Batch #2 )
TFR-101
DCS-101
RBR-101
SDLB-102
RBS-101
SDLB-101
SDLB-104
DSBS-101
SDLB-103
RBS-102
DBS-101
Total Occ.T ime (Batch #3 )
TFR-101
DCS-101
RBR-101
SDLB-102
RBS-101
SDLB-101
SDLB-104
DSBS-101
SDLB-103
RBS-102
DBS-101
Total Occ.T ime (Batch #4 )
TFR-101
DCS-101
RBR-101
SDLB-102
RBS-101
SDLB-101
SDLB-104
DSBS-101
SDLB-103
RBS-102
DBS-101
h48 96 144 192 240 288 336 384 432 480 528 576 624 672 720 768 816 864 912 960 1008 1056 1104 1152h
day2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50day
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G-2: Gantt Chart of the Downstream Process for 1 Section (SuperPro Designer v8.5) 
 
 
Total Occ.T ime
V-101
DS-101
SDLB-106
DE-103
SDLB-107
DF-103
DF-101
SDLB-101
MA-101
SDLB-102
DE-101
SDLB-103
C-101
DF-102
DE-102
SDLB-104
SDLB-105
FDR-101
Total Occ.T ime (Batch #2 )
V-101
DS-101
SDLB-106
DE-103
SDLB-107
DF-103
DF-101
SDLB-101
MA-101
SDLB-102
DE-101
SDLB-103
C-101
DF-102
DE-102
SDLB-104
SDLB-105
FDR-101
Total Occ.T ime (Batch #3 )
V-101
DS-101
SDLB-106
DE-103
SDLB-107
DF-103
DF-101
SDLB-101
MA-101
SDLB-102
DE-101
SDLB-103
C-101
DF-102
DE-102
SDLB-104
SDLB-105
FDR-101
h8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136 144 152h
day1 2 3 4 5 6day
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Appendix H: WHO Summary Protocol [12] 
 
Summary protocol for influenza vaccine (inactivated) 
(master/working seed lot Type A or Type B) 
 
The model summary protocol that follows is provided as general guidance to manufacturers. It is 
not intended to constrain them in the presentation of data relevant to the complete review of the 
quality control tests performed on the vaccine. It is important to note that satisfactory test results 
do not necessarily imply that the vaccine is safe and effective, since many other factors must be 
taken into account, including the characteristics of the manufacturing facility. 
 
Name and address of manufacturer 
 
Laboratory reference no. of lot 
 
Date when the processing was completed 
 
Information on manufacture 
 
Virus used to inoculate eggs or cells for the manufacture of the lot: 
(a) strain and substrain 
(b) passage level 
(c) source and reference no. 
(d) remarks 
 
Results of sterility test 
 
Results of tests for extraneous agents 
 
Results of tests on adjuvant (if any) 
 
Conditions of storage 
 
Monovalent virus pool Type A or Type B 
 
Name and address of manufacturer 
 
Laboratory reference no. of virus pool 
 
Virus used to inoculate eggs or cells. 
(a) master seed strain and source 
(b) passage level of master seed 
(c) working seed lot, reference no. and source 
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Date of inoculation 
 
Date of harvesting allantoic or amniotic fluids or cell culture fluids 
 
Storage conditions before inactivation 
 
Date of inactivation 
 
Time of inactivation 
 
Method of inactivation 
 
Concentration of inactivating agent 
 
Storage conditions after inactivation 
 
Concentration/purification procedure 
 
Antibiotics used during preparation, if any 
 
Identification of adjuvant added, if any 
 
Tests on monovalent pool 
Test for absence of viable influenza virus 
 
No. of eggs or cell culture vessels inoculated 
 
Incubation time and temperature 
 
Date of test 
 
Results 
 
Determination of haemagglutinin content 
 
Method 
 
Date of determination 
 
Results 
 
Tests for presence of neuraminidase (if performed) 
 
Method 
 
Date of test 
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Results 
 
Virus disruption (for split vaccine) 
 
Method 
 
Date 
 
Results 
 
Purity (for subunit vaccine) 
 
Method 
 
Date 
 
Results 
 
Purity (for cell-derived vaccine) 
 
Method 
 
Date 
 
Results 
 
Identity tests 
 
Method 
 
Date of test 
 
Results 
 
Test for extraneous agents (if performed) 
 
Method 
 
Date 
 
Results 
 
Final bulk 
 
Name and address of manufacturer 
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Identification of final bulk 
 
Identification of monovalent virus pool used to prepare final bulk 
 
Date of manufacture 
 
Control of final bulk 
 
Preservative(s) added and concentration 
 
Any other substances added and concentration 
 
Determination of haemagglutinin content 
 
Method 
 
Date of determination 
 
Results 
 
Sterility 
 
Date of test 
 
Results 
 
Total protein content 
 
Method 
 
Date of test 
 
Results 
 
Ovalbumin content (egg-derived vaccines) 
 
Method 
 
Date of test 
 
Results 
 
Test for residual DNA (if performed) 
 
Method 
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Date 
 
Results 
 
Test for adjuvant (if performed) 
 
Method 
 
Date 
 
Results 
 
Tests for chemicals used 
 
Date of tests 
 
Results 
 
Final lot 
Identity test 
 
Method 
 
Date of test 
 
Results 
 
Sterility 
 
Method 
 
Date of test 
 
Results 
 
Determination of haemagglutinin content 
 
Method 
 
Date of determination 
 
Results 
 
Innocuity (if performed) 
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No. and species of animals 
 
Doses injected 
 
Period of observation 
 
Date of test 
 
Results 
 
Endotoxin content 
 
Method 
 
Date of test 
 
Results 
 
Inspection of final container 
 
Results 
 
Other tests 
 
Additional comments (if any) 
A sample of a completed final container label and package insert should be attached. 
 
Certification by producer 
 
Name of head of production of the final vaccine 
 
Certification by head of the quality assurance department taking overall responsibility for 
production and control of the final vaccine: 
 
I certify that lot no . . . of influenza vaccine (inactivated), whose number appears on the label of 
the final container, meets all national requirements and satisfies Part A of the Requirements for 
Biological Substances No. 17, revised 1990. 
 
Signature: _______________ 
Name (typed): __________________ 
Date: ___________________ 
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Certification by the national controller 
 
If the vaccine is to be exported, provide a copy of the certificate from the national regulatory 
authority as described in section B.2, a label of a final container, and a leaflet of instructions to 
users. 
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Appendix I: Model Certificate from the WHO [12] 
 
Model certificate for the release of influenza vaccine (inactivated) 
 
The following lots of influenza vaccine (inactivated) produced by _________ in _________ 
whose numbers appear on the labels of the final containers, meet all national requirements, Part 
A of the Recommendations for Influenza Vaccine (Inactivated) (revised 2003) and the 
recommendations for good manufacturing practice and quality assurance for biological products. 
 
 
Lot Number Date of Last Potency Test by 
Manufacturer 
Expiry Lot Number 
 
 
  
 
 
As a minimum, this certificate is based on examination of the manufacturing protocol. 
 
The number of this certificate is: _________________________ 
 
The Director of the National Control Laboratory (or Authority as appropriate): 
 
Name (typed): __________________________ 
 
Signature: _________________________ 
 
Date: ____________________ 
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Appendix J: Sample Piping and Instrumentation Diagram 
 
Production
Reactor
LI
Oxygen In
OIC
HI
tC
Oxygen 
Content 
Controller
Level Indicator
Pure Media Flow
From Previous Reactor
pH Indicator
TC
SC
TI
Timed Controller
Ventilation Out
Electrical Heating Coil
Cooling Water In Cooling Water Return
Rot. Speed Controller
Temp. Indicator
Temp. Controller
Switch
Operator Additions
Flow Out to Next Process
PI AS
Pressure Indicator
Alarm Controller/Siren
 
 
The level indicating controller controls both the rotational mixer speed and the flow into the 
tank.  The rotational speed is automatically set by an operator, but if at any given time the 
surface of the liquid becomes too turbulent for the indicator to read, the rotational speed 
controller will slow the motor down. 
 
The temperature controller will move cooling water or run the heating coil, based on the set point 
and the indicated temperature.  If it is too hot, the switch is flipped open and the cooling water 
valve is opened, turning off the electricity and the water on.  If it is too cold, the switch is closed, 
and the valve closed, leading to the heat being turned on and the cooling water turned off. 
 
The pH indicator merely outputs the pH to any nearby operator.  If at any given time the pH 
becomes too high or too low, the operator can add standard solutions into the reactor to try to 
increase or decrease the pH.  However, the literature indicates this should not be an issue. 
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The vent allows for exiting gasses to be removed.  It is assumed that the bag/reactor is slightly 
above atmospheric pressure due to the vent, i.e., no pressure builds up, just flow through.  
However, if pressure builds up (i.e., the valve gets shut), then an indicator will monitor the 
pressure.  At a certain psig, the alarm controller will set of a siren, alerting area operators that the 
reactor has a pressure build up in it that needs to be immediately rectified. 
 
There will be two options for the alarm unit to use, which is not indicated by the diagram.  The 
first is a low pressure alarm.  This means that pressure has built up and needs to be rectified, but 
catastrophic failure is not imminent if the issue is rectified.  The second alarm is a high pressure 
alarm.  This alarm alerts operators to immediately clear the area and try to quickly rectify the 
issue.  Should this alarm go off, it means catastrophic failure is immediately imminent if the 
situation is not rectified. 
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Appendix K: Sample HAZOP Analysis 
 
 
Equipment Reference and Operating Conditions Deviations Causes? Consequences Additional Consequences Process Indicators
Production Reactor Level
Less Media Runs Dry Pump Cavitation Pump Damage LI, tC
Previous Reactor not Empty Product Loss Potential Contamination
Media Flow Valve Open/Broken Releases Contamination tC
Previous Reactor Valve Open/Broken Releases Contamination, Exposure
Tank Rupture Releases Contamination, Exposure
More Too much Media Loaded Overfill Rupture LI
Backflow from Downstream Overfill Rupture LI
None Same as Less
Pressure
Less Too low flow from oxygen Product Loss Reactor Implosion DIC, PI
Too little media flow in See Level Less tC, LI, PI
Line Rupture Releases Contamination DIC, TC, tc, LI, PI
Tank Rupture Releases Contamination, Exposure PI, LI
More Too much from oxygen Over Oxygenation Product Loss, Ruptures DIC, PI, AS
Media flow too high Overfill Rupture tC, PI, AS
Ventilation Valve Broken Releases Contamination PI, AS
None Rupture Releases Contamination, Exposure PI, LI, AS
Temperature
Less Oxygen Valve Stuck Open Product Loss Rupture DIC, TI
Electrical Switch Broken Product Loss TI, TC
Cooling Water Valve Stuck Open Product Loss Rupture of Cooling Jacket TI, TC
More Cooling Water Valve Stuck Closed Product Loss Tank Melts/Rupture TI, TC
Electrical Switch Broken Product Loss Tank Melts/Rupture TI, TC
pH
Less Operator added too much acid Product Loss Tank Rupture HI
Too much oxygen Product Loss Tank Rupture HI
Tank Rupture Releases Contamination, Exposure HI
More Operator added too much base Product Loss Tank Rupture HI
Reaction proceeded to long Product Loss HI
Tank Rupture Releases Contamination, Exposure HI
Oxygenation
Less Oxygen Valve Stuck Closed Product Loss DIC
Oxygen Line Rupture Releases Contamination DIC
More Oxygen Valve Stuck Open Over Pressurization Rupture, Releases DIC
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Mixer Speed
Less Set point too low Product Loss SC
Controller broken Product Loss Motor Damage SC
Motor broken Product Loss Motor Damage SC
More Set point too high Motor Damage Motor Destruction SC
Controller broken Motor Damage Motor Destruction SC
Level indicator broken Product Loss Motor Destruction LI, SC
Disruption to reactor Rupture Contamination, Exposure SC
